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Key to abbreviations 
 
BDCA = blood dendritic cell antigen 
CCL = chemokine (C-Cmotif) ligand 
CCR = chemokine (C-C motif) receptor 
CXCR = chemokine (C-X-C) receptor 
CD = cluster of differentiation 
CLA = cutaneous lymphocyte antigen 
CLP = common lymphoid progenitor 
CMP = common myeloid progenitor 
DC = dendritic cell 
DC-SIGN = dendritic cell-specific intercellular adhesion molecule-3-grabbing non 
integrin 
Flt3-L = fms-like tyrosine kinase-3 ligand 
GM-CSF = granulocyte-macrophage colony-stimulating factor 
HLA = human leukocyte antigen 
ICAM = intercellular adhesion molecule 
IFN = interferon 
IL = interleukin 
LC = Langerhans cell 
LPS = lipopolysaccaride 
MCP = monocyte chemoattractant protein 
M-CSF = macrophage colony-stimulating factor 
mDC = myeloid dendritic cell 
MHC = major histocompatibility complex 
MHC-I = major histocompatibility complex class I molecules 
MHC-II = major histocompatibility complex class II molecules 
MIP = macrophage inflammatory protein 
MMP = matrix metalloproteinase 
NF-κB = nuclear factor κB 
NK = natural killer 
NLR = NOD-like receptors 
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NP = nanoparticle 
pDC = plasmacytoid dendritic cell 
PPAR = peroxisome proliferator-activated receptor 
PPRE = peroxisome proliferator response elements 
RANTES = regulated upon activation normal T cell expressed and secreted 
RunX3 = runt-related transcription factor 3 
RXR = retinoid X receptor 
SCF = stem cell factor 
SDF = stromal cell-derived factor 
SPARC = secreted protein acid and rich in cystein 
STAT = signal transducer and activator of transcription 
TGF = transforming growth factor 
TLR = Toll-like receptor 
TNF = tumor necrosis factor 
TPO = thrombopoietin 
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Abstract  
 
 Dendritic cells are specialized to capture antigens, process them and present 
them to T cells to initiate, regulate and fine tune immune responses towards pathogens 
and tumours. Therefore these cells play crucial roles in infection, cancer, allergy, 
autoimmunity and graft rejection. Besides immunity, they can cause anergy and trigger 
active tolerance, depending on the microenvironment conditions. Dendritic cells are 
heterogeneous for origin, anatomical localization, phenotype and function. Two subsets 
are recognized, myeloid and plasmacytoid dendritic cells. Myeloid cells include 
Langerhans cells, the dendritic cells of non-lymphoid connective tissue and those of 
lymphoid tissue and lymph. Langerhans cells are found in the epidermis and some 
mucosal epithelia and have an unique antigenic and morphological profile. They express 
langerin and contain special inclusions evident at the electron microscopy, i.e. Birbeck 
granules. The myeloid dendritic cells of non-lymphoid connective tissue express high 
levels of DC-SIGN/CD209. 
 In vivo, myeloid dendritic cells differentiate from haematopoietic stem cells-
derived precursors and localize in peripheral tissues, afterwards they migrate from sites 
of antigen uptake to lymphoid organs and during this process mature to antigen 
presenting cells capable of interacting with lymphocytes and stimulate both immune 
response and peripheral tolerance to self. Dendritic cells express peroxisome 
proliferator-activated receptors (PPAR)-γ. These receptors are involved in many 
regulatory pathways, such as those regarding lipid, lipoprotein and glucose metabolism, 
inflammation, endothelial function, cancer and bone morphogenesis. The stimulation of 
PPAR-γ on dendritic cells in vitro has been reported to have controversial effects.  
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 Knowledge of the stages and mechanisms of control of the differentiation of 
dendritic cells is a necessary premise to exercise control over these cells, useful for 
medical purposes. In this research the differentiation potential into myeloid dendritic 
cells in vitro and the effect of rosiglitazone, an agonist of PPAR-γ, on that 
differentiation have been evaluated for three different precursors collected from human 
peripheral blood, precisely CD14+ monocytes, CD34+ progenitors and CD133+ 
progenitors. Moreover, the cells differentiated from CD14+ monocytes were evaluated 
for their interaction with inorganic nanoparticles. 
 The cells were isolated from buffy coats obtained from healthy donors by 
magnetic separation, upon labelling with colloidal superparamagnetic microbeads 
conjugated with mouse anti-human CD14, CD34 or CD133 monoclonal antibodies, and 
were cultured with different cytokines depending on the cell type, for 9 d (CD14+ 
monocytes) or 18 d (CD34+ and CD133+ precursors); rosiglitazone (1 µmol/l) was 
added in some experiments; the differentiation stages and the characteristics of the cells 
generated at the end of culture were observed. Each experiment (with and without 
rosiglitazone) was made with cells of a single donor. 
 The generated cells were analyzed by light microscopy, electron microscopy, 
immunofluorescence, flow cytometry, mixed lymphocyte reaction and real-time PCR. 
Cells obtained from CD14+ monocytes after 7 d culture (i.e. immature dendritic cells) 
were incubated for up to 48 h with gold and silica nanoparticles, 10 and 100 µg/ml, and 
evaluated for their ability to uptake those nanoparticles and for the intercellular 
compartments of destination.  
 All precursors generated large dendritic cells that strongly expressed HLA-DR 
antigens and exhibited lymphocyte-stimulating activity in mixed lymphocyte reaction. 
Moreover, CD34+ and CD133+ precursors generated also medium size dendritic cells, 
with fewer organelles and less well developed dendrites than large dendritic cells, and 
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small, lymphocyte-like cells poor in organelles. 
 A proportion of large cells, increasing from those generated from CD14+ 
monocytes to those generated from CD34+ precursors to those generated from CD133+ 
precursors, expressed CD1a and langerin/CD207; in flow cytometry these cells were all 
included among those with higher side scatter, while large dendritic cells with low side 
scatter did not express langerin/CD207. Many cells from any culture expressed DC-
SIGN/CD209, even together with langerin/CD207. Rudimentary Birbeck granules were 
observed only occasionally by electron microscopy in large dendritic cells from any 
precursor. Variable percentages of large dendritic cells expressed surface molecules 
related to maturation, the highest numbers were among cells generated from CD133+ 
precursors. 
 Rosiglitazone led to more mature features at electron microscopy in all cases 
(looser chromatin texture, increase in organelles especially lysosomes) and to more 
numerous cells expressing langerin/CD207 in cells generated from CD34+ and CD133+ 
precursors, the latter effect was significant for cells generated from CD133+ precursors. 
 Freshly isolated CD14+ monocytes expressed a low number of copies of mRNA 
for PPAR-γ; the expression increased during culture, independent of the addition of 
rosiglitazone. Freshly isolated CD34+ cells showed a much lower expression of PPAR-
γ gene than CD14+ monocytes and the expression remained low throughout culture. 
Freshly isolated CD133+ cells showed a number of copies of mRNA for PPAR-γ higher 
than CD14+ monocytes; this expression increased during culture although with great 
variability among experiments; the response to rosiglitazone was also variable among 
experiments, with a trend towards increase of PPAR-γ mRNA. 
 Immature dendritic cells absorbed gold and silica nanoparticles by endocytosis 
and concentrated them in lysosomes; using fluorescent silica nanoparticles it was found 
that the amount of particles internalized depended on the concentration of particles in 
  10
the medium and reached a maximum within 4 h, then remained stable with time. The 
presence of nanoparticles and their absorption did not influence the structure, 
immunophenotype and lymphocyte-stimulating capacity of dendritic cells, as evaluated 
by electron microscopy, flow cytometry and mixed lymphocyte reaction respectively. 
 These results indicate that the differentiation potential of hematopoietic cells 
into myeloid dendritic cells with different phenotypes changes with the progression of 
spontaneous in vivo differentiation towards monocytes and that the specific orientation 
towards Langerhans cells begins very early. The differentiation degree achieved in vitro 
does not match entirely that seen in vivo, which indicates that more environmental 
factors are relevant in this respect than those that can be reproduced in vitro. CD133+ 
cells, which are the most immature progenitors, express PPAR-γ and, if transferred into 
culture, maintain this expression, that increases during differentiation. Therefore the 
possibility arises that PPAR-γ agonists or antagonists may be used to modulate this 
differentiation. Indeed, cells generated from all precursors tested in this research 
appeared to respond to the PPAR-γ agonist rosiglitazone at the morphological level, 
with signs of improved differentiation towards more mature dendritic cells. Immature 
myeloid dendritic cells proved able to incorporate inorganic nanoparticles without 
apparent damage, at least within the time of culture of the present experiments, which 
opens the way to explore the possible use of those particles in medicine. 
 Since dendritic cells play crucial roles in infection, cancer, allergy, 
autoimmunity and graft rejection, thorough knowledge of their subsets differentiation 
and behaviour will open the path to tools allowing better control of those cells in 
clinical conditions. 
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Introduction  
 
 The immune system grants for both innate and adaptive responses to pathogens, 
which depend on different cell types and functions. The innate immune system involves 
granulocytes, mast cells, macrophages and natural killer cells. These cells use non-
clonal recognition receptors, including lectins, Toll-like receptors (TLRs), NOD-like 
receptors (NLRs) and helicases, to provide quick but generic responses to pathogens. 
The adaptive immune system response depends on B and CD4+ and CD8+ T cells 
which use clonal receptors that specifically recognize antigens or their derived peptides 
presented by antigen presenting cells and grant for immunological memory (Paluka and 
Banchereau, 2012).  
 Dendritic cells (DCs), macrophages and B cells may act as antigen presenting 
cells; DCs, in particular, are specifically devoted to capture and process antigen since 
primary response. DCs express several specialized molecules, as the major 
histocompatibility complex (MHC) and a combination of costimulatory molecules and 
adhesion molecules for the presentation of antigen to T cells in order to initiate the 
immune response. They are also known as dendritic leukocytes and are the most 
efficient cells for antigen presentation, being able to elicit T cell response even in very 
low numbers and to stimulate primary as well as secondary response, thus explaining 
their nickname of “professional antigen presenting cells” (Steinman, 2012). The 
interaction between DCs and lymphocytes during the initiation of an adaptive immune 
response is one of the most important control points to ensure that the immune response 
is correct and to direct this response towards reaction or tolerance to pathogenic 
organisms (van Panhuys, 2017) and tumours. DCs are also responsible for the 
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peripheral tolerance to self and play crucial roles in allergy, autoimmunity and 
transplant rejection. 
 Owing to their properties, DCs are often called “nature adjuvants” and have been 
proposed for immunotherapy upon antigen loading (Von Bubnoff et al., 2001; Paluka 
and Banchereau, 2012). However, clinical trials have not yet gone beyond preliminary 
phases and the limited knowledge on the biology of these cells, both alone and in the 
context of tissues, may well be a cause of failure. Indeed cancer therapeutic strategies 
using DC-based immunotherapy alone or in combination with radiation therapy and 
chemotherapy developed until now have been only partially effective, mainly because 
there are no techniques yet to monitor the behaviour of DCs in vivo (Ahn et al., 2017). 
The more advanced strategy is the use of DC-based vaccines, consisting in DCs loaded 
with tumour antigens, that are infused into the patient and generate anti-tumour T-cell 
responses from CD8+ effector T-cells (Kumar et al., 2017). 
 Despite their origin from CD34+ bone marrow hematopoietic stem cells, DCs 
are heterogeneous and many subsets have been identified both in mice and humans 
(Bancherau and Steinman, 1998; Paluka and Banchereau, 2012; Steinman, 2012). The 
most important DC subsets are myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) 
(Dzionek et al., 2000; Shigematsu et al., 2004). The latter are so called because of well 
developed rough endoplasmic reticulum and less prominent cell projections as 
compared with mDCs. Knowledge of pDC cell biology is less advanced than that of 
mDCs. 
 Among mDCs, Langerhans cells (LCs) are peculiar for localization, molecular 
phenotype and morphology. They are in an immunologically immature state and 
localize within epidermis and stratified squamous mucosal epithelia where they can 
efficiently take up and process a wide variety of antigens, including contact sensitizers, 
tumor-associated and microbial antigens. LCs express E-cadherin, CD1a and 
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langerin/CD207 and contain Birbeck granules, a unique organelle detected at electron 
microscopy (Valladeau et al., 2000; Romani et al., 2003). E-cadherin is used to remain 
in contact with surrounding epithelial cells (Romani et al., 2010). CD1a is a pattern 
recognition receptor for lipoarabinomannan, a non-polymorphic bacterial molecule to be 
presented to T lymphocytes (Adams 2014). Langerin/CD207 is a c-type lectin localized 
not only at the cell surface, but also in the endosomal recycling compartment, in 
Birbeck granules and in other tubular and vesicular structures (Valladeau et al., 2000; 
Romani et al., 2003). Due to their position and the various types of antigens recognized, 
LCs are critical for the induction of immune responses towards pathogens and tumours 
and are credited to play a pathogenic role in allergic skin diseases (Paluka and 
Banchereau, 2012 , Von Bubnoff et al., 2001). 
 
 
Dendritic cells history  
 The story of these cells began almost one and a half century ago and the interest 
for them is ever growing because of their central role in immunobiology. 
 In 1868 Paul Langerhans described for the first time the dendritic epidermal 
cells which were thereafter designated with his name. The LC have been indeed the first 
DC discovered, other DCs have then been found within lymphoid organs, epithelia, 
connective tissue and lymph (reviewed by Pimpinelli et al., 1994). In the 1950s LCs 
were considered as melanocytes that had lost the capacity to make melanin pigment 
(Masson, 1948; Breathnach, 1965). At the beginning of the following decade Birbeck et 
al. (1961) demonstrated the presence of LCs in vitiligo, showing that they were not 
melanocytes, and by electron microscopy identified a characteristic organelle, which 
thence on has been designated Birbeck granule.  
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 Recognition of DCs as a population specific for differentiation and function has 
come through three distinct lines of research (Hoefsmit et al., 1982; Fossum, 1989; 
Metlay et al., 1989). 
 A first line of research, started in the 1970s, was represented by microscopic 
studies on lymphoid organs and tumours. These studies were aimed at defining the 
proliferative diseases of the lymphoid organs and included a detailed description of the 
cell types present in the lymphoid organs. Cells with dendritic shape were identified 
among the stromal elements of the T-dependent areas of secondary lymphoid organs 
(Veldman, 1970; Kaiserling and Lennert, 1974). These cells have cytoplasmic 
extensions that make contact with other similar cells and lymphocytes, for this feature 
have been called interdigitating cells or interdigitating reticulum cells. Veerman (1974) 
proposed that the interdigitating cells in the thymus-dependent area of the rat spleen 
form a microenvironment allowing T cells to differentiate and proliferate. Bone marrow 
precursors give rise to these cells, that migrate into lymphoid organs via peripheral 
tissues and lymphatics, becoming interdigitating reticulum cells (Kelly et al., 1978; 
Hoefsmit et al., 1979). A role has been proposed for these cells also in directing the 
structural organization of lymphoid tissue in T-cell lymphomas (Ribuffo et al., 1983), 
including those of the skin (Romagnoli et al., 1986; Pimpinelli et al., 1994). 
 A second line of research was the histopathological analysis of dermatological 
immune-mediated diseases, where LCs were found in contact with lymphocytes in the 
inflamed skin (Silberberg-Sinakin, 1973; Silberberg et al., 1976). It was concluded that 
LCs are implicated in allergic reactions and in other immunologic reactions, so that they 
were regarded as cells of immune system (Rowden et al., 1977; Stingl et al., 1977); they 
were also recognized to derive from progenitors present in the bone marrow (Katz et al., 
1979; Perreault et al., 1984; Goordyal and Isaacson, 1985). Studies in the mouse and 
humans demonstrated the antigen-presenting function of LCs (Stingl et al., 1978; 
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Braathen and Thorsby 1980; Green et al., 1980; Bjercke et al., 1984). LCs were 
eventually recognized as members of the DC family of the immune system (see below) 
and their life cycle was analyzed in the mouse (Schuler et al., 1985).  
 Steinman's group (Steinman and Cohn, 1973, 1974) started a third line of 
research, isolating cells with a peculiar dendritic shape from the mouse spleen, hence 
their designation as dendritic cells. It was then demonstrated that DCs present 
exogenous antigen to T cells in an MHC-restricted fashion and can induce specific 
cytolytic T cell responses by cross-priming lymphocytes (Bevan, 1976). These cells 
have a low phagocytic activity and stimulate T-dependent immune responses very 
efficiently, in particular the proliferation and maturation of helper T cells to effectors 
elements. Although they are not the only cells in the body with this property, DCs seem 
to be mandatory for the stimulation of primary immune responses (reviewed by Metlay 
et al., 1989). High expression of major histocompatibility complex class II molecules 
(MHC-II), of which the principal representative in humans is HLA-DR, is instrumental 
to that function (Steinman e Witmer, 1978 Steinman et al., 1979) even if it is not 
enough to explain their differential role in respect to other MHC-II expressing cells. 
 Human DCs in peripheral blood were characterized in detail by Van Voorhis et 
al. (1982). It was also reported that the T cell areas in lymphoid organs are the main 
location where DCs are found and activate T cells which, once activated, may leave the 
lymph node and migrate to sites of inflammation (Witmer et al., 1984). Indeed, DCs 
were discovered to be responsible for the activation of naïve T cells, that subsequently 
interact with B cells and stimulate them to generate plasma cells and produce antibodies 
(Inaba and Steinman, 1985). Witmer-Pack et al. (1987) documented the requirement of 
granulocyte-macrophage colony stimulating factor (GM-CSF) for DC maturation. 
Moreover, it was shown that T cells fail to proliferate upon antigen presentation in the 
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absence of co-stimulatory signals and instead become unresponsive to further activation 
(Jenkins and Schwartz, 1987). 
 Later on, cells with abundant rough endoplasmic reticulum (like plasma cells) 
but with irregular cell surface were shown to behave as antigen presenting cells and to 
be able to secrete huge amounts of type I interferons (IFN; Fitzergerald-Bocarsly, 1988; 
Facchetti et al., 1989). They were first designated plasmacytoid T cells or plasmacytoid 
monocytes and later on have been recognized as a peculiar type of DCs, named pDCs 
(Cella et al., 2000; Colonna et al., 2002; see McKenna et al., 2005, for review), which 
are - among others - associated with protection from opportunistic infections (Siegal et 
al., 1999). The other DCs, including LCs, have been designated mDCs (Banchereau and 
Steinman, 1998). pDCs have been associated with protection from opportunistic 
infections (Siegal et al., 1999). 
 In the last decade of the XX century it was observed that DCs are also able to 
effectively stimulate the activation of CD8+ cytotoxic T lymphocytes (Young and 
Steinman, 1990; Shen et al., 1997), the differentiation of plasma cells from B 
lymphocytes (Fayette et al., 1998) and the survival of plasmablasts (De Vinuesa et al., 
1999). The B7-1/CD80 and B7-2/CD86 ligands and their receptors on T cells, 
respectively CD28 and CTLA-4 (cytotoxic T lymphocyte antigen-4), were identified as 
crucial regulators of T cell responses and additional co-stimulatory molecules were 
identified on DCs (Springer, 1990; Caux et al., 1994a; Caux et al., 1994b). A method 
was devised to obtain DCs from monocytes (Sallusto and Lanzavecchia, 1994), 
allowing to study the basic functions of DCs in humans. Also, studies in apparently 
different model organisms led to the identification of TLR, first in the fruit fly and then 
in the mouse (Lemaitre et al., 1996; Poltorak et al., 1998), and DCs were shown to 
express these receptors, possibly implied in antigen recognition and capture (Medzhitov 
et al., 1997). It was eventually shown that DCs are involved also in tolerance and 
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immune regulation (Banchereau and Steinman, 1998), although the details on when 
these functions, instead of immune activation, occur and how they are regulated remain 
still unclear. 
 In the new millennium, the calcium dependent, C-type lectin receptor (CLR) 
DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin) was found to be expressed by mDCs and to mediate transient adhesion with T 
cells, necessary for their activation (Geijtenbeek et al., 2000a, 2000b). C-type lectin 
receptors (CLRs) are an important family of pattern recognition receptors: they interact 
with pathogens through the recognition of mannose, fucose and glucan carbohydrate 
structures and are involved in the induction of specific gene expression profiles in 
response to specific pathogens, either by modulating TLR signalling or by directly 
inducing gene expression (Geijtenbeek, 2009).  
 Plasmacytoid DCs were shown to regulate events during the course of viral 
infections, atopy, autoimmune disease, and metastatic cancer (Liu, 2005; McKenna et 
al., 2005).  
 Given their potential to stimulate both innate and adaptive antitumor response, 
during the past few decades DCs have been the subject of numerous studies seeking 
new immunotherapeutic strategies against cancer (Kumar et al.2017). The basic concept 
behind the use of DCs in immunotherapy relies on the intrinsic antigen-presenting 
properties of DCs to elicit a potent tumour antigen-specific T-cell-driven immune 
response (Figdor et al., 2004; Tacken et al., 2007; Palucka and Banchereau, 2012; 
Klechevsky and Banchereau, 2013; Tel et al., 2013). DCs have also been used in 
nanoparticle (NP)-based immunotherapeutic strategies trying to take advantage of such 
particles - most frequently organic - to deliver immunogenic molecules to antigen 
presenting cells. Little information is available regarding inorganic-NP-mediated DCs 
stimulation (Shen et al. 2016). 
  18
 
 
Maturation and function of dendritic cells 
Migration of dendritic cell precursors and dendritic cells through body compartments 
 Myeloid DCs differentiate to an immature, antigen absorbing phenotype and 
then proceed to a mature, lymphocyte stimulating phenotype. The precursors of mDCs 
enter tissues and quickly differentiate to immature mDCs. Immature DCs are 
characterized by a high capacity for antigen capture and processing and low T cell 
stimulatory ability, because they express low levels of co-stimulatory molecules and 
have a limited capacity to secrete cytokines (Engering et al., 1997; Palucka and 
Banchereau, 2012). Circulating DC precursors may also directly encounter pathogens, 
which induce secretion of cytokines that in turn can activate eosinophils, macrophages 
and NK cells (Palucka and Banchereau, 2012). After antigen capture, DCs migrate to 
lymphoid organs MHC-II molecules on the cell surface together with co-stimulatory 
molecules, leading to the selection of circulating antigen-specific lymphocytes. During 
this process DCs lose the ability to absorb antigens and come to express the co-
stimulatory molecules CD54, CD80 and CD86 together with increased amounts of 
MHC-II, as well as a peculiar chemokine ()C-C motif) receptor (CCR), precisely CCR7, 
that allows them to localize to lymphoid tissues. Maturation requires the ligation of 
CD40 and is associated with the expression of the maturation marker CD83 and the 
acquisition of the ability to secrete cytokines (Cella et al., 1997; Steiman, 2012). Once 
arrived to lymphoid tissue, DCs localize in the para-follicular zone and differentiate into 
interdigitating cells to activate naive T-cells. DCs are able to polarize the immune 
response to either Th1 o Th2 types and to improve T cell memory (Steinman et al., 
2003) by the production of different cytokines that determine the classes of immune 
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response (Bancherau et al., 2000). Furthermore a few DCs move to the germinal centers 
where they collaborate with T lymphocytes to initiate B cell mediated immune 
responses. DCs can activate naïve and memory B cells (Bancherau et al., 2000) and 
induce the differentiation of activated-naïve B cells to plasma cells by the secretion of 
interleukin (IL)-12 and IL-6 (Dubois et al., 1998). 
 In turn, activated T cells help DCs to achieve terminal maturation, further 
promoting the expansion and differentiation of lymphocytes themselves. It is believed 
that, after interaction with lymphocytes, DCs die by apoptosis (Banchereau et al., 2000).  
 Interaction between DCs and T cells during primary responses occurs within 
lymphoid tissue, which is reached by naïve T cells from the circulation. During 
secondary T cell-mediated responses, DCs can interact with lymphocytes also in 
peripheral and inflamed tissues (Fujita et al., 2011; Eyerich and Novak, 2013; Trucci et 
al., 2013), also on account of the fact that memory T lymphocytes circulate also through 
peripheral tissues (Shin et al., 2013). 
 The maturation of pDCs occurs before entering the circulation; the steps and 
regulation of this process are still under investigation. Swiecki and Colonna (2015) have 
emphasized that pDCs express MHC-II and the co-stimulatory molecules CD40, CD80 
and CD86 and can present antigens to CD4+ T cells, albeit not as efficiently as myeloid 
DCs (Reizis et al., 2011); when pDCs receive activation signals through TLRs or other 
pattern recognition receptors, they act as immunogenic cells. 
 
Antigen capture  
 Antigen capture may occur in several ways. Immature DCs can internalize large 
amounts of material through macropinocytosis, through fluid phase and receptor-
mediated endocytosis (Engering et al., 1997; Mommas et al., 1999), and through 
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phagocytosis of apoptotic and necrotic cell fragments (Albert et al., 1998), viruses, 
bacteria and parasites (Inaba et al., 1993; Rescigno et al., 1999; Banchereau et al., 
2000). 
 Receptors that have been identified on DCs include lectins such as the mannose 
receptor langerin/CD207, DC-SIGN/CD209 and DEC-205/CD205, Fc receptors such as 
FcεRI, FcγR type I (CD64) and type II (CD32) (Engering et al., 1997; Banchereau et al., 
2000), and TLRs (Erbacher et al., 2009). The mannose receptor, langerin/CD207 
(Romani et al., 2003) and DC-SIGN/CD209 (Geijtenbeek et al., 2000) contain multiple 
carbohydrate-binding domains; mannose receptor in particular is involved in the 
internalization of sugar-containing proteins and mediates phagocytosis of various 
microorganisms which expose mannosylated glycoproteins (Engering et al., 1997). 
DEC-205/CD205 has in its extracellular portion a cysteine-rich domain, a fibronectin 
type II domain and multiple C-type lectin-like domains and in the cytoplasmic portion 
an amino acid motif which efficiently targets the endocytosed molecule to late 
endosomes/class II compartments (Mahnke et al., 2000; Erbacher et al., 2009). TLRs 
are able to recognize a broad spectrum of different pathogen-associated molecular 
patterns, including conserved components of protozoa, bacteria, fungi, and viruses 
(Takeda and Akira, 2005). The recognition of microbial components by DC TLRs 
results in the expression of inflammatory cytokines and co-stimulatory molecules 
followed by antigen presentation, linking innate to acquired immunity. FcγRI/CD64 and 
FcγRII/CD32 are members of a family of cell surface molecules which includes also 
FcγRIII/CD16 and bind the Fc portion of Ig G (van de Winkel et al., 1993). Binding to 
FcγRs leads to endocytose immune complexes or opsonized particles (Fanger et al., 
1996; Amigorena et al., 1998; Döbel et al., 2013). CD1 proteins are known as non-
classical antigen-presenting molecules and bind microbial lipid and glycolipid antigens 
to present them to T cells (Peiser et al., 2003; Porcelli and Modlin, 1999). Four CD1 
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proteins (CD1a-d) are expressed by mDCs; LCs express almost exclusively CD1a and 
CD1c (Elder et al., 1993; Banchereau et al., 2000); humans pDC do not express CD1d 
(Montoya et al., 2006). The phagocytosis of apoptotic cells is restricted to the immature 
stage of DC development, and this process is accompanied by the expression of some 
receptors as CD36, that recognizes apoptotic cells (Savil, 1997; Albert et al., 1998). 
Upon maturation, these receptors and the phagocytic capacity of DCs are 
downmodulated (Albert et al., 1998). 
 The phagocytosis of uninfected, apoptotic cells may lead to prevent immune 
responses against self antigens within or on the surface of dying cells (Fadeel et al., 
2010); the responsible cells (macrophages, but possibly also DCs) would acquire a "pro-
resolution" phenotype and protect against firing inflammation. Alternatively, the 
phagocytosis of apoptotic cells which hosted infectious agents is critical for the 
induction of a subset of T cells involved in host defense against infections, which may 
also become involved in autoimmunity and tissue inflammation (Torchinsky et al., 
2009). 
 
Antigen processing and presentation 
 Antigens captured by immature DCs are degraded in endosomes. The generated 
polypeptides are transported into the MHC class II-rich compartment (which is part of 
the endosomal compartment) and are loaded on HLA-DR II molecules, while DCs 
mature. Mature DCs reduce their endocytic capacity in favour of high surface levels of 
MHC and co-stimulatory molecules, which make them capable of activating even naïve 
T lymphocytes. The peptide-MHC-II complex is exported to the cell surface, where it 
remains stable for days and is available for recognition by CD4+ T cells (Chow and 
Mellman, 2005; Cresswell, 2005). DCs can also load nascent MHC-I molecules with 
antigenic peptides which derive not only from newly synthesized molecules but also 
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from controlled proteolysis of exogenous ones in the proteasome followed by transfer 
into the endoplasmic reticulum through TAP (transporter associated with antigen 
processing: Reits et al., 2000). The peptide-MHC-I complex is transferred to the cell 
surface and is recognized by CD8+ T cells (Banchereau et al., 2000), leading to cross-
priming (Ackerman and Cresswell, 2004; Whiteside et al., 2004). The pathway from 
endosome to cytosol, where the proteasome is located, is still obscure. Recognition of 
MHC-peptide complexes on DCs by antigen-specific T cell receptor (TCR) constitutes 
the primary signal in DC-T cell interaction, necessary to stimulate a T-lymphocyte 
response (Hart, 1997). The activation of T cells is facilitated by the interaction of 
membrane molecules expressed by these cells, LFA-1 (a CD11b CD18 heterodimer) 
and CD2, with co-receptors expressed by antigen presenting cells, respectively LFA-
3/CD58 and ICAM-1/CD54 (Wang et al., 2003). These bonds are in synergy with TCR-
mediated signals and promote efficient intercellular adhesion, T cell proliferation and 
differentiation (Zumwalde et al., 2013). Although presentation of antigen to TCR is 
necessary for the initiation of T cell activation, further co-stimulatory signals delivered 
by antigen presenting cells (and also by neighbour cells) are needed for full-blown 
immune response (Caux et al., 1994a). Interactions between co-stimulatory molecules 
expressed by DCs and their ligands expressed by T cells are among those signals 
(Banchereau et al., 2000). In turn, ligation of CD40 on DCs by CD40-ligand 
(CD40L/CD154) expressed by lymphocytes stimulates the maturation of DCs, with the 
consequent expression of high levels of MHC-II, CD80 (B7-1) and CD86 (B7-2), the 
latter two molecules are ligands for CD28 on lymphocytes and stimulate secretion of 
cytokines by the latter cells (Caux et al., 1994a). Contemporaneous block of the 
interactions mediated by CD54 and CD80 or CD86 leads to anergy (Caux et al., 1994b; 
Wang et al., 2003; Palucka and Banchereau, 2012). 
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Dendritic cells and regulation of tolerance 
 Besides being immunostimulatory, DCs also induce tolerance in the thymus 
(central tolerance) and in the periphery (peripheral tolerance). In the thymus this 
depends on deletion of autoreactive T cells and differentiation of CD4+ T lymphocytes 
to CD4+ CD25+ Treg cells. DCs present self-antigens to thymocytes in the thymic 
medulla: if T cells have too high affinity for self-antigens, such as occurs with 
autoreactive T cells, they are deleted by negative selection (Bancherau and Steinman, 
1998; Rathmel and Thompson, 2002). 
 In peripheral lymphoid organs anergy or active tolerance may be induced 
(Bancherau and Steinman, 1998; Steinman et al., 2003). If DCs come to present an 
antigen while remaining immature, e.g. because of antigen load in the absence of 
inflammatory signals, antigen-specific CD4+ and CD8+ T cells undergo transient 
activation and proliferation followed by deletion which establishes antigen-specific T 
cell tolerance (Probst et al., 2014). In these immature, or semi-mature conditions DCs 
express the Th1-inducing cytokine IL-12, which is part of a tolerogenic phenotype of 
these cells (Steinman et al., 2003). T cells may go into apoptosis induced via Fas/Fas-
ligand pathway (Süss and Shortman, 1996) or through activation of the pro-apoptotic 
mitochondrial protein Bim (Chen et al., 2007). Another pathway leading to tolerance is 
activation of CD4+ CD25+ Treg cells, which provide active suppression of response to 
self and to not-self antigens (Steinman et al., 2003; Fehérvari and Sakaguchi, 2004); 
also these cells are stimulated by DCs (Probst et al., 2014). 
 Immune suppression is elicited by Treg cells through secretion of soluble 
factors, such as the immunosuppressive cytokines IL-10 and transforming growth factor 
(TGF)-β, and through intimate cell contact (Fehérvari and Sakaguchi, 2004). Among 
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other effects, IL-10 and TGF-β inhibit the maturation of DCs. Treg cells express on 
their cell surface molecules, such as CTLA-4/CD152 and lymphocyte activation gene 3 
protein (LAG3/CD223), that suppress DC activation. CTLA4/CD152 mediates the 
down regulation of its ligands, the co-stimulatory molecules CD80 and CD86 on DCs - 
that are capable of interacting both with CTLA4/CD152 and CD28 (Carreno et al., 
2002) - or even the trans-endocytosis of their extracellular domain by lymphocytes, and 
triggers the induction of the enzyme indoleamine 2,3-dioxygenase (IDO) (Fallarino et 
al. 2003; Probst et al., 2014) that catalyzes the conversion of tryptophan to kynurenine 
and other metabolites which have potent, short-range immunosuppressive effects 
(Fehérvari and Sakaguchi, 2004). LAG3/CD223 is a CD4-related transmembrane 
protein that binds MHC-II on DCs and suppresses their maturation and 
immunostimulatory capacity (Liang et al., 2008). Finally, Treg stimulate an increase in 
the cytoplasmic levels of cyclic adenosine monophosphate (cAMP) in DCs and thus 
suppress their activation. This may occur by transfer of cAMP from Treg cells to DCs 
via gap junctions (Probst et al., 2014) and through the generation of pericellular 
adenosine from extracellular nucleotides by the ectoenzymes CD39 and CD73 (Probst 
et al., 2014). The effects of extracellular adenosine are mediated by the four members of 
the P1 purinergic G-protein coupled receptor (GPCR) family (A1, A2A, A2B and A3), 
which are expressed on both mDCs and pDCs (Hasko et al., 2008). Binding to A2A and 
A2B causes stimulation of adenylate cyclase and subsequent increase in intra-cellular 
cAMP, whereas A1 and A3 have an opposing effect (Challier et al., 2013). A2A 
receptor activation on mature DCs shifts their cytokine profile from a pro-inflammatory 
to an anti-inflammatory one, with increased production of IL-10 (Hasko et al., 2008). 
 An example of physiological immune tolerance occurs in the gut, where Treg 
cells maintain immune homeostasis and prevent effector cells from causing 
immunopathology in response to commensal bacteria. Here macrophages secrete IL-1β 
  25
upon sensing microbial products in the gut; this cytokine triggers a subset of innate 
lymphoid cells (ILC), precisely ILC3, to produce GM-CSF; and GM-CSF exposed DCs 
release retinoic acid, which promotes the generation of Treg cells (Aychek and Jung, 
2014). ILCs are found in the intestine, lung, skin and liver and are divided into three 
groups depending on the cytokines secreted; ILC3 secrete mainly IL-17 and IL-22 
(Hazenberg at al., 2014). 
 The mechanisms of tolerance are activated also during pregnancy and allow 
conception, embryo implantation and foetus development (Hsu and Nanan, 2014; 
Schumacher and Zenclussen, 2014). The foetus is semiallogeneic since it expresses 
antigens of both maternal and paternal origin and the immune system of pregnant 
women must defend both the mother and foetus from foreign pathogens while tolerating 
the semiallogeneic foetus. It has been shown that maternal immune T cells specifically 
recognize paternal alloantigens but pregnancy induces a state of transient T cell 
tolerance specific for those antigens (Tafuri et al., 1995; La Rocca et al., 2014). The 
exposure of the female reproductive tract to seminal fluid can promote paternal antigen-
specific hyporesponsiveness, inducing a state of transient active immune tolerance in 
the mother (La Rocca et al., 2014). The seminal fluid contains potent immune-
regulatory molecules such as TGF-beta and PGE2-related prostaglandins, which 
promote the generation of Treg from CD4+ CD25- T cells (Robertson et al., 2009) and 
the conversion of DCs to a tolerogenic phenotype (Schumacher and Zenclussen, 2014). 
The continuous release of conceptus-derived paternal antigens into the maternal 
circulation allows Treg cells to continue emerging and expanding throughout 
pregnancy, migrate to the uterus and contribute to the generation of a friendly 
environment for the embryo. In peripheral blood, Treg cells are likely involved in the 
suppression of maternal effector T cells responsive to foetal antigens (Schumacher and 
Zenclussen, 2014). 
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 Some tissues are endowed with an immune privilege, so that foreign antigens do 
not induce a conventional immune response; specifically this happens in the eye and 
brain (Medawar, 1961). DCs and macrophages come to the eye through blood and are 
localized in some ocular tissues, predominantly the uvea (iris, ciliary body and choroid); 
few cells enter the peripheral retina and cornea. When ocular tissues are perturbed, bone 
marrow-derived cells carrying antigen from the eye are found in the lymph nodes and 
the antigens are detected even in the spleen after several hours (Forrester and Xu, 2012). 
Nonetheless, the local response may be low or absent, in order to preserve the 
transparency of the eye. Several mechanisms have been proposed to explain ocular 
immune privilege, including induction of Treg cells, the expression of molecules such 
as Fas or CTLA4/CD152 and the secretion of cytokines that generate an 
immunosuppressive microenvironment (Stein-Streilein, 2008; Denniston et al., 2011; 
Wang et al., 2011). 
 
 
Subsets of dendritic cells  
 Dendritic cells derive from hematopoietic stem cells (see reviews by Steiman, 
1991, and Cella et al., 1997). DC progenitors in the bone marrow give rise to circulating 
precursors that home to tissues, where they reside as immature cells (Banchereau et al., 
2000). DCs are a heterogeneous cell population whose members may acquire diverse 
maturation states and functions (Schmidt et al., 2012). As anticipated, in both humans 
and mice two distinct types of DCs have been identified, mDCs and pDCs. The origin 
of the former is from common myeloid progenitor cells, while that of the latter has yet 
to be conclusively defined (Bancherau and Steinman, 1998; Dzionek et al., 2000; 
Shigematsu et al., 2004). 
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 During differentiation DCs may go through an immature and a mature phase. 
The transition of mDCs to maturity is marked by modifications of the 
immunophenotype and the acquisition of strong immunostimulatory power 
(Villadangos and Heath 2005; Johnson and Ohashi, 2013). LCs are part of the immature 
DCs (Shortman and Caux, 1997; Hubert et al., 2005). pDCs appear in blood as already 
mature (McKenna et al., 2005). 
 
Myeloid dendritic cells 
 Myeloid CD34+ progenitors differentiate into monocytes (CD11c+ CD14+ DC 
precursors) that yield immature mDCs in response to GM-CSF and IL-4 (Sallusto and 
Lanzavecchia, 1994), and macrophages in response to macrophage colony stimulating 
factor (M-CSF).  
 Myeloid DCs typically express CD11c, MHC-II (in our species, human 
leukocyte antigen-D Related, i.e. HLA-DR), CD33 and CD40, moreover upon 
maturation they express CD83 and the co-stimulatory molecules CD54, CD80 and 
CD86 (Freeman et al., 1995; Banchereau et al., 2000). They are specialized for antigen 
presentation through MHC-II to CD4+ T-cells (Banchereau et al., 2000; Lewis and 
Reizis, 2012), but can also present antigens to CD8+ T-cells and interact with natural 
killer (NK) cells (Albert et al., 1998; Moretta et al., 2003).  
 Immature mDCs may be found in any connective tissue proper; a subset, i.e. 
LCs are found also within epithelia (see below). Mature mDCs reside in T areas of the 
lymphoid tissue including the spleen white pulp (Banchereau et al., 2000). 
 Peripheral blood contains mDC precursors (Banchereau and Steinman, 1998), 
immature (Bancherau et al., 2000) and mature mDCs (Franks et al., 2013), pDCs (Liu, 
2005) and so called inflammatory DCs (see below; Schäkel et al., 2002). The subsets of 
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DCs in peripheral blood may be distinguished by the differential expression of three 
cell-surface molecules: CD1c, also know as BDCA-1, CD303 or BDCA-2, CD141 or 
BDCA-3 and CD304 or BDCA-4. BDCA-1/CD1c is expressed by mDCs (Palucka and 
Banchereau, 2012). The expression of BDCA-2/CD303 and BDCA-4/CD304 is 
confined to pDCs, as described below (Bancherau et al., 2000; Dzionek et al., 2000; 
Palucka and Banchereau, 2012; Franks et al., 2013). BDCA-3/CD141 is expressed by 
mDCs with high capacity to capture exogenous antigens for presentation on MHC-I 
class molecules, such as epidermal Langherans cells, also described later. 
 In stratified squamous epithelia of the skin and mucosae mDCs are represented 
by LCs, which express E-cadherin, CD1a and langerin/CD207, and in connective tissue 
there are interstitial DCs, which express CD1c, DC-SIGN/CD209, DEC205 and, 
sometimes, also CD1a. There are phenotypic and functional differences between these 
two cell types, as detailed below (Nestle et al., 1993; Palucka and Banchereau, 2012; 
Klechevsky and Banchereau, 2013). mDCs are also observed in lymph vessels as veiled 
cells and in lymphoid tissue as interdigitating cells, as detailed below. 
 
Langerhans cells 
 Langerhans cells are located in stratified squamous epithelia of the epidermis 
and mucosae. They have an oval body and some long branches. The nucleus is indented, 
with pale chromatin except for a thin peripheral rim. The cytoplasm contains 
cytoskeletal intermediate filaments not clustered into fibrils, mitochondria, few 
cisternae of rough endoplasmic reticulum, many smooth vesicles and tubules, a large 
Golgi apparatus and Birbeck granules (Montagna and Parrakkal, 1974).  
 The Birbeck granules are disc shaped with a central paracrystalline array of 
particles and a dilated rim along part of their margin, so in transverse section they 
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appear as rods, with parallel membranes on either side enclosing a central striated 
lamella, and are sometimes dilated at an end, resembling a tennis racket (Birbeck et al., 
1961 and Wolff, 1967; Rodriguez and Carosi, 1978).  
 Birbeck granules are found exclusively in LCs of human and other mammals, 
but not in other DCs. They are part of an endocitic pathway and are implicated in 
antigen processing. Antilangerin antibodies are internalized upon binding to the cell 
surface, and delivered to Birbeck granules (Valladeau et al., 2000). Some authors 
believe that these inclusions also traffic between the endosomal compartment and the 
plasma membrane along the recycling route (McDermott, 2002). Birbeck granules are 
closely associated with the expression of langerin/CD207; transfection of langerin 
cDNA leads to Birbeck granule formation in fibroblasts (Valladeau et al., 2000), 
however not all langerin positive cells exhibit Birbeck granules when observed at 
electron microscopy (see below). 
 Langerin/CD207 is a mannose-specific C-type lectin (Romani et al., 2003); an 
intracellular epitope of this molecule is Lag antigen (Valladeau et al., 2000). 
Langerin/CD207 recognizes mannose, n-acetylglucosamine, fucose and sulfated sugars; 
it binds microbial fragments and pathogens such as HIV and Candida albicans 
(Mizumoto and Takashima 2004; Idoyagaet al., 2008). Remarkably, langerin/CD207 
can be found in cells also in the absence of Birbeck granules (Uzan-Gafsou et al., 2007; 
Bonetti et al., 2011) and can reside in endosomal structures independent of those 
granules (Valladeau et al., 2000; Romani et al., 2003).  
 Another characteristic marker of LCs is CD1a, that has been identified before 
langerin/CD207; it recognizes lipid antigens and can participate in the uptake and 
presentation of non-polymorphic molecules of bacterial cell wall (Mizumoto and 
Takashima 2004). CD1a is transported from the cell surface to early recycling vescicles 
and Birbeck granules; glycolipid antigens captured by langerin/CD207 are also 
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internalized to these granules, where CD1a is coupled with lipid moieties. This pathway 
enables LCs to uptake specific lipid and glycolipid antigens and to present them via 
CD1a to T cells (Hunger et al., 2004). 
 This indicates that LCs have a role in the presentation of non-peptide antigens to 
T cells, mediated by the LC-specific pattern-recognition receptor langerin/CD207 as 
well as the antigen-presenting molecule CD1a. The location of LCs in the epidermis 
allows the innate immune system to respond rapidly to microbial invaders in the skin 
(Hunger et al., 2004). Targeting of non-peptide antigens to LCs may therefore become a 
vaccine strategy that could be used for the generation of immunity to cutaneous 
pathogens. 
 Langerhans cells express other molecules such as the myeloid markers CD13 
and CD33 (Valladeau et al., 2005), DEC205/CD205, DCIR (dendritic cell 
immunoreceptor)/CLEC4A (C-type lectin domain family 1 member-4A)/CD367, TLRs 
including TLR 1, 2, 3, 6 and 10 (respectively CD281, CD282, CD283, CD286, CD290), 
the high affinity receptor for the crystallizable fragment of immunoglobulins G 
(FcγRI/CD64a), that for the third component of the complement system (C3R/CD11b 
CD18), interleukin-2 receptor (IL2R/CD25 CD122 CD132), MHC class I (HLA-A, B 
and C in humans) and class II (HLA-D, DR, DP in humans) molecules, the lymphocyte 
common antigen CD45, ICAM-1/CD54, the integrin molecules of the CD11/CD18 
family - i.e. CD11a, CD11b, CD11c and CD18 - (see for review: Romagnoli et al., 
1991; Klechevsky and Banchereau, 2013) and E-cadherin/CD324, which mediates the 
binding of LCs to keratinocytes in epidermis (Jakob et al., 1999), plays a role in cell 
migration and is expressed even by some DCs in the blood (Blauvelt et al., 1995). The 
presence of E-cadherin/CD324 may be important also for adherence to carcinoma 
epithelial cells. LCs also express the cutaneous lymphocyte antigen (CLA/CD162) 
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which is a ligand for E-selectin/CD62E (Koszik et al., 1994), that in basal conditions is 
specifically expressed by skin endothelial cells (Ley, 2003). 
 As already stated, myeloid CD34+ progenitors differentiate into monocytes 
(CD11c+ CD14+ DC precursors) that yield immature DCs in response to GM-CSF and 
IL-4 (Sallusto and Lanzavecchia, 1994), and macrophages in response to M-CSF. 
Myeloid progenitors also differentiate into CD11c+ CD14- precursors, which yield LCs 
in response to GM-CSF, IL-4 and TGF-β, and macrophages in response to M-CSF 
(Bancherau et al., 2000). Myeloid progenitors can differentiate into LCs also through 
CD1a+ CD14- precursors, generated upon five days culture of CD34+ cells with GM-
CSF and tumour necrosis factor (TNF)-α, by continuing culture with the same factors 
for seven more days (Caux et al., 1996; Cella et al., 1997). A research of Geissmann et 
al. (1998) has shown that also CD14+ monocytes cultured with GM-CSF, IL-4 and 
TGF-β can give rise to LCs containing Birbeck granules, however this result has not 
been confirmed by other studies. In the literature the differentiation of LCs from 
monocytes has given inconstant results, and most often the generated cells did not show 
a strong polarization of differentiation into LCs. Good results have been obtained in the 
differentiation of LCs starting from CD34+ or CD133+ stem cells, isolated from cord 
blood (Hubert et al., 2005; Bonetti et al., 2014). The differentiation of LCs is dependent 
on TGF-beta, as indicated by the fact that TGF-beta 1 knockout mice totally lack 
epidermal LCs while bone marrow cells from these mice can give rise to LCs after 
transfer into wild type recipients. Thus, the lack of LCs in TGF-beta 1-deficient mice is 
not a result of a defect in bone marrow precursors but of the production of TGF-beta 1 
within the microenvironment where LC differentiate (Borkowski et al., 1996). 
 Therefore it is actually conceived that DCs may arise from dedicated circulating 
precursors in steady state ("classical" or "conventional" DCs) and from monocytes in 
inflammation (Kushwah and Hu, 2011). 
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 The bone marrow precursors of the LCs pass into the circulation, migrate into 
tissues through the wall of blood vessels and enter epithelia crossing the basement 
membrane (reviewed by Romagnoli et al., 1991). The influence of the epithelial 
microenvironment induces the maturation of precursor cells into LCs; it cannot be 
excluded that CD1 antigen may be acquired by these cells even before they enter the 
epithelium, while Birbeck granules appear after this entry (Bani et al., 1988). In situ, 
some cells express low levels of CD40, CD83 and CD86, but not CD80. Isolated LCs 
express high levels of all these antigens, which reflect enhanced expression during cell 
isolation (McLellan et al., 1998). LCs behave as immature DCs, able to capture antigens 
but expressing low levels of co-stimulatory molecules and with a limited capacity to 
secrete cytokines (Paluka and Banchereau, 2012). These cells acquire co-stimulatory 
molecules and secrete abundant cytokines upon maturation, a process that occurs during 
migration of these cells from the epidermis to lymph nodes and is accompanied by 
down-regulation of E-cadherin/CD324 and langerin/CD207 and loss of Birbeck 
granules (Tang et al., 1993; Romani et al., 2001; Van den Bossche et al., 2012), not 
always complete (Schuler, 1991). 
 Langerhans cells are also capable of transferring endocytosed antigens into the 
cytoplasm, process them and eventually present them on the cell membrane within 
MHC-I class molecules, to stimulate CD8+ T lymphocytes (Palucka and Banchereau, 
2012). LCs stimulate CD8+ T responses also through secretion of IL-15, that is critical 
for promoting differentiation of naive CD8+ T cells into granzyme B+ cytotoxic 
lymphocytes (Klechevsky and Banchereau, 2013). The turn over in the epidermis is not 
high: LCs in the epidermis are long-living. This may in part be attributed to the 
longevity of individual LCs within the epidermal environment, in part to a low level of 
cell division in the periphery (Romani et al., 2003). Blood-borne precursors are 
recruited to the epidermis in large numbers only in inflammatory states of the skin: two 
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cytokines are critical for immigration of LC precursors into the inflamed skin: TGF-β 
and macrophage inflammatory protein (MIP)-3α/chemokine (C-C motif) ligand 
(CCL)20 (Borkowski et al., 1996; Merad et al., 2002; Schmuth et al., 2002). MIP-3α is 
produced by keratinocytes and LC precursors express the appropriate receptor, 
CCR6/CD196 (Dieu et al., 1998). 
 
Dendritic cells of non-lymphoid connective tissue  
 The normal human dermis hosts highly dendritic cells (Headington, 1986). Some 
of them express factor XIIIa in normal and diseased skin (Cerio et al., 1989; Nestle et 
al., 1993; Muszbek et al., 2011). The normal skin contains three separate populations of 
dermal DCs, which have distinctive phenotypic markers. Nestle et colleagues (1993) 
showed that factor XIIIa positive dermal DCs may be negative for CD1a and CD14, 
positive for CD1a only or positive for CD14 only and that the expression of CD1a is 
anyway weaker than that of LCs. CD14+ dermal DCs express C-type lectins, including 
DC-SIGN/CD209, LOX-1 (lectin-like oxidized LDL receptor-1), CLEC-6 (C-type 
lectin domain family 1 member-6)/CLEC4D/CD368, CLEC7A/dectin-1/CD369, 
DCIR/CLEC4A/CD367; they also express TLRs, such as TLR2, 4, 5, 6, 8, 10/CD282, 
CD284, CD285, CD286, CD288, CD290 (Klechevsky et al., 2009). The DC-
SIGN/CD209 expression is not restricted to DCs in normal dermis but is expressed also 
by macrophages together with other monocyte/macrophage markers, as CD14, CD68, 
CD163, and CD206 (Ochoa et al., 2008; Töröcsik et al., 2014). The cytotoxic 
lymphocyte response induced by CD14+ dermal DCs is less potent than that induced by 
LCs. In addition, CD4+ T cells primed by CD14+ dermal DCs are unique in their ability 
to promote antibody response, either directly or by priming T follicular helper (TFH)-like 
CD4+ T cells (Klechevsky and Banchereau, 2013). CD14+ dermal DCs secrete IL-10, 
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that limits cytotoxic lymphocyte response and induces regulatory T cells (Treg or Tr), 
and express Ig-like transcript (ILT)-2 and ILT-4, inhibitors of CD8 binding to MHC-I 
because of sterical hindrance. Conversely, CD1a+ dermal DCs, like LCs, secrete IL-15 
in immunological synapses, inducing a cytotoxic response (Klechevsky and 
Banchereau, 2013). Moreover, even if both LCs and dermal DCs are effective in 
stimulating immune responses, LCs seem to be particularly effective in stimulating 
responses to low concentrations of antigens, while dermal DCs are primarily 
responsible for the response to high dose haptens (Bacci et al., 1997). Low 
concentrations of antigens may be found in the early stages of viral infection and 
carcinogenesis (Romagnoli, 2001). 
 
Dendritic cells in lymph and lymphoid organs 
 During maturation DCs come to express CCR7/CD197 that allows their 
localization to lymphoid tissue, upon migration through lymph vessels and lymphoid 
tissue in order to efficiently launch immune responses (Paluka and Banchereau, 2012). 
While in transit through lymph vessels, DCs acquire a peculiar morphology with wide 
lamellipodia, for which they have been called veiled cells (Hoefsmit et al., 1982; 
Bancherau et al., 2000). During maturation DCs process the captured antigen into small 
fragments which are then conjugated with MHC-II and MHC-I class molecules for the 
presentation to CD4+ and respectively CD8+ T cells in order to initiate the immune 
response (Paluka and Banchereau, 2012; Bancherau and Steinman, 1998). 
 In the spleen there are marginal DCs and in the T-cell rich areas of lymph nodes 
there are interdigitating reticulum cells, which present antigens to T-lymphocytes 
(Bancherau et al., 2000; Palucka and Banchereau, 2012). The name evokes the cell 
shape, indeed they have long branches running among lymphocytes. The nucleus is 
large, convoluted and lined by a thin band of chromatin (Veldman and Kaiserling, 1980; 
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Steinman et al., 1997). LCs, peripheral connective tissue DCs, veiled cells and 
interdigitating reticulum cells are all closely related. The latter two types may contain a 
few Birbeck granules when they come from the epidermis and mucosal squamous 
stratified epithelia (Schuler et al., 1991).  
 
Dendritic cells in the thymus 
 Dendritic cells are present also in the thymus, where they are key players during 
thymocyte development because they present self antigens and induce negative 
selection of potential auto-reactive T-cell clones (Vandenabeel et al., 2001). Those cells 
are localized almost exclusively in the medulla (Brocker, 1999; Steinman et al., 2003), 
which seems to be a major site of deletion of thymocytes upon positive selection 
(Hengartner et al., 1988; Sprent and Webb, 1995). Thymic DCs are presumably 
comparable to those of other tissues for antigen capture and processing. This would lead 
to the production of MHC-peptide complexes, needed to delete self-reactive T cells; 
indeed, the cells that express a T-cell receptor (TCR) with specificity for self antigens 
are removed (Spits, 2001; Steinman et al., 2003). The human thymus contains two 
populations of mature DCs, expressing different lineage markers and displaying 
different capacities for IL-12 secretion; the latter is necessary for the negative selection 
of thymocytes (Lúdvíksson et al., 1999). The major thymic DC population is 
distinguished by being CD11b- and expresses markers of fully mature DCs. The minor 
thymic DC population is CD11b+. Both populations are CD4+ (Vandenabeel et al., 
2001). After CD40 ligation only CD11b- thymic DCs release substantial amounts of IL-
12, while CD11b+ DCs release scarce amounts of this cytokine (Lúdvíksson et al., 
1999; Vandenabeel et al., 2001). 
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Inflammatory dendritic cells 
 Inflammatory DCs can be found in peripheral blood and in tissues upon 
inflammation (Hespel and Moser, 2012). They have been designated as 6-sulfo acetyl-
N-lactosamine (LacNAc)+ DCs (‘slanDCs’) based on the expression of that residue on 
the P-selectin glycoprotein ligand 1 membrane molecule, also known as M-DC8 
(Schäkel et al., 2002)/CD162. They express transcription factors involved in DC 
differentiation, including DC specific ZBTB46 (Satpathy et al., 2012), and their 
differentiation does not depend on GM-CSF, at variance with conventional DCs (Greter 
et al., 2012). Inflammatory DCs are able to induce the differentiation of Th17 
lymphocytes (Segura et al., 2013) and take part in adaptive and innate immunity 
(Hespel and Moser, 2012; Segura and Amigorena, 2013). 
 
Plasmacytoid dendritic cells 
 The CD11c- CD14- DCs, or pDCs, spontaneously express high levels of DC-
SIGN/DEC-205 and do not express CD1d; on mDCs these molecules are upregulated 
upon in vitro culture or LPS treatment (Vremec and Shortman, 1997). Moreover, pDCs 
regularly express CD11b, CD32 (FcRγ), CD123 (IL-3R) and - in mice - DC specific 
33D1 antigen (Nussenzweig et al., 1982; Dudziak et al., 2007; Benitez-Ribas et al., 
2008). Initially pDCs were considered to derive from lymphoid CD34+ progenitor cells 
(Bancherau et al., 2000; Shigematsu et al., 2004), but it has been shown that they are 
produced in the bone marrow and, in steady-state conditions, circulate in the blood and 
migrate to lymphoid tissues. At variance with mDCs, they exit the bone marrow already 
fully differentiated (Sawai et al., 2013). They represent 0.2%-0.8% of peripheral blood 
mononuclear cells (Liu, 2005) and can migrate to and accumulate in inflammatory sites 
where they may contribute to the inflammatory response by releasing cytokines and 
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chemokines and activating lymphocytes (Zhang and Wang, 2005). In physiological 
conditions pDCs are localized in the spleen white pulp and in lymph nodes but not in 
peripheral tissues (Liu et al., 2005). Circulating pDCs express BDCA-2/CD303 and 
BDCA-4/CD304, which are expressed also on pDCs in the bone marrow. BDCA-
2/CD303 is a novel type II C-type lectin that can internalize antigen for presentation to 
T cells (Dzionek et al., 2001), BDCA-4/CD304 is identical to neuropilin-1, a neuronal 
receptor recognizing both the axon guidance factors belonging to the class-3 
semaphorin subfamily and vascular endothelial growth factor (VEGF) and expressed 
also on endothelial and tumour cells (Dzionek et al., 2002). Its role in pDCs is still 
obscure. Moreover pDCs express TLR7, 8 and 9/CD287, CD288, CD289 (Zhang and 
Wang, 2005). These cells represent a front line of anti-viral immunity owing to their 
ability to secrete large amounts of IFNα in response to viruses (Siegal et al., 1999). At 
an early stage of viral infection, pDCs produce large amount of interferon (IFN)-α and -
β (type I IFN; Dzionek et al., 2000) and can then differentiate into antigen presenting 
cells (Siegal et al., 1999; Zhang and Wang, 2005). The pDC-derived IFNα may also 
promote the activation of NK cells and the maturation of other subsets of DCs, thus 
helping to activate novel T and B cell clones (Zhang and Wang, 2005; Palucka and 
Banchereau, 2012). IFN-α also has an autocrine effect (McKenna et al., 2005). pDCs 
appear highly efficient at cross-presenting antigens to CD8+ T lymphocytes, using pre-
synthesized stores of MHC-I molecules to stimulate a rapid cytotoxic response to viral 
infections; moreover they upregulate the expression of MHC-II molecules by mDCs and 
induce the maturation of these cells to antigen presenting cells thanks to the secretion of 
IFN-α and TNF-α. pDCs can also be tolerogenic by stimulating CD4+ CD25+ Treg cells 
(Banchereau and Steinman, 1998; Liu, 2005; Zhang and Wang, 2005; Dudziak et al., 
2007; Palucka and Banchereau, 2012), which may be particularly important in case of 
intracellular infections and tumours (McKenna et al., 2005). Some studies have reported 
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that pDCs recruited to the tumour microenvironment often display a non-activated state 
and are associated with tumour progression and poor outcome, especially in cases of 
breast, cancer, lung and skin cancer (Treilleux et al., 2004; Jensen et al., 2012; Labidi-
Galy et al., 2012; Rega et al., 2013). 
 
 
Dendritic cells and disease 
 
Langerhans cells in pathology 
Neoplasia 
 Substantial alterations in the frequency, distribution, and phenotype of LCs 
occur in pathological conditions. 
 Langerhans cell histiocytosis results from the clonal proliferation of 
immunophenotypically and functionally immature, round LCs. This conditions is 
characterised by inflammatory lesions containing abundant CD1a positive and CD207-
positive cells (Haroche et al., 2017), that show high expression of costimulatory 
molecules (Laman et al., 2003) and contain Birbeck granules which are pathognomonic 
of the disease (Harrist et al., 1983). 
 Oral squamous cell carcinoma is the most frequent malignant tumour of the 
oral cavity and the sixth most common cancer in the world. It may develop from oral 
epithelial dysplasia. LCs from the oral epithelium can present tumour antigens to T 
cells, activating an anti-tumour response. The LC counts in normal, dysplastic and 
cancerous oral epithelia have given controversial results (Wang et al., 2017). A gradual 
decline in LC number has been reported at first during the progression of oral 
carcinogenesis (Upadhyay et al., 2012), while further studies have described a gradual 
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increase in LC number from normal oral mucosa to dysplasia to squamous cell 
carcinoma (Costa et al., 2016). Wang et colleagues (2017) found a significantly lower 
LC number in oral dysplastic lesions with malignant transformation than in those 
without malignant transformation. A high number of LCs in the latter lesions indicates 
that the patient has the ability to elicit an immune response against the dysplastic cells. 
Thus, a low LC number in the lesions progressing to cancer suggests at least a partial 
loss of immunosurveillance against dysplastic cells; this in turn favours the malignant 
transformation of a dysplastic lesion into cancer. The authors interpreted the findings to 
indicate that the patient has the ability to elicit an immune response against the 
dysplastic cells and that a drop in that response is related to at least partial loss of 
immunosurveillance against dysplastic cells which may favour the malignant 
transformation. The issue is still open to debate, because the above reported results of 
Costa et al. (2016) remain contradictory to the latter hypothesis. 
 Malignant melanoma can lead to changes in LC population thus altering the 
host-against-tumour response. Already thirty years ago it was proved that melanoma-
associated LCs decline in number as melanoma progress (Stene et al., 1988). Melanoma 
is one of the most aggressive forms of human cancer and is considered one of the most 
immunogenic tumours: it has been suggested that the number and the maturation state 
of LCs could correlate positively with an overall better prognosis of the patient (Neagu 
et al., 2013; Dyduch et al., 2017). Immature or incompletely matured DCs, in turn, may 
mediate tolerance instead of immune activation (Toriyama et al., 1993). 
 A study in vitro on LCs generated from CD34+ hematopoietic stem cells has 
shown that melanoma-derived factors may play a role at an early LC differentiation 
stage, preventing the generation of LCs from their precursors. Thus, CD34+ progenitors 
leaving the blood circulation and entering the dermis at the tumour site would be unable 
to generate LCs and repopulate the epidermis because of the inhibitory factors secreted 
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by melanoma cells (Berthier-Vergnes et al., 2001). The observations that dermal LCs 
are not found around deeply invasive melanomas (Stene et al, 1988) while tumour 
infiltrating CD1 cells are detected in the dermis deep to melanoma (Toriyama et al, 
1993) reinforce this hypothesis. The naturally occurring LC turnover thus appears 
severely impaired inducing a decline in the number of epidermal LCs (Berthier-Vergnes 
et al., 2001). The regression of primary cutaneous melanoma has been associated with 
the presence of LCs infiltrating the tumour (Ma et al., 2013). 
 Another type of analysis on cells taken from sentinel lymph nodes of melanoma 
patients has shown that LCs cells in those nodes have feature of immature rather than 
mature LCs (Gerlini et al., 2012a). 
 
Viral diseases 
 Dendritic cells have a major role in immune defence against viral infection by 
generating and regulating innate and adaptive immune responses (Randolph et al., 2005; 
Woodham et al. 2016). LCs have been investigated in relation to viral diseases because 
of their proximity to pathogen entry portals of the epidermis and mucosae (Merad et al., 
2008), including sexually transmitted ones (Botting et al., 2017). 
 Human immunodeficiency virus-1 (HIV-1) can infect DCs and can transmit 
the virus to lymphocytes which in turn can exfoliate the virus in the environment. This 
virus therefore manipulates the natural function of DCs to interact with CD4+ T cells, 
which are the main target of HIV and in which rapid replication occurs (Ahmed et al., 
2015; Botting et al., 2017). The receptors used by HIV to enter DCs and LCs are CD4, 
that is a primary receptor for glycoprotein envelope gp120, and CCR5/CD195 or 
CXCR4/CD184 that can act as coreceptors. Entry through these pathways can yield 
productive infections. Alternatively, HIV has been shown to interact with DC-
SIGN/CD209 and langerin/CD207 at the surface of DCs and LCs respectively. 
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Association with DC-SIGN/CD209 promotes HIV infection, binding gp120 and 
cointernalizing the virus (Woodham et al. 2016); this can result in viral transmission to 
T cells via trans-infection, through immune synapse (Woodham et al. 2016). HIV has 
been detected by immunoelectron microscopy in Birbeck granules, presumably upon 
adhesion to langerin/CD207 (de Witte et al., 2007). In patients with HIV infection the 
onset of opportunistic cutaneous and oral infections is more likely, as facial and perioral 
molluscum contagiosum or oral candidiasis; the latter opportunistic infection is 
presumably favoured by alterations in number and differentiation state of lymphocytes 
and LCs that have been found in these patients (Ficarra et al., 1994; Romagnoli et al., 
1997). 
 Molluscum contagiosum and other viral infection, such as warts and condyloma 
acuminatum, may depend on interactions between virus and LCs for the pathogenesis 
(Bhawan et al., 1986). Molluscum contagiosum is caused by a poxvirus (Epstein, 1992; 
Gold and Moiin, 2007; Leung at al., 2017) and the lesions are usually small, discrete, 
pearly and dome-shaped with central umbilication, but atypical and rare varieties could 
be found in some patients, in whom the lesions may be large, confluent or non-
umbilicated (Yin and Li, 2017). A total absence of Langerhans and indeterminate cells 
was observed in molluscum contagiosum, while their number appeared to be normal or 
increased in the perilesional normal skin (Bhawan et al., 1986). 
 Warts are caused by human papilloma viruses (a double-stranded DNA virus) 
and quite common (Gold and Moiin, 2007; Thappa and Chiramel, 2016). Warts are 
clinically identified as papular or nodular structures that have a horny layer on their 
surface; they can range from 1-2 mm to several centimetres in size and may become 
confluent leading to the appearance of even larger lesions; viral replication takes place 
in differentiated keratinocytes in or above the stratum granulosum (Gold and Moiin, 
2007). In verruca vulgaris and plantar warts few LCs and indeterminate cells were seen 
  42
in the suprabasal location, while normal numbers were noted in the perilesional skin 
(Bhawan et al., 1986). Jackson et al. (1994) studied epidermal LC number in the warts, 
in 75% of cases their number was reduced in comparison with normal skin. A decrease 
in LCs and a lack of adhesion molecule expression in the epidermis of warts may lead 
to a reduced influx of T cells into the lesion itself, although T cells are present in the 
dermis underlying the infected site (Jackson et al., 1994). Thus the reduction of LCs 
may lead to a poor immune response (in particular, T cell-mediated immunity) to the 
virus in the epidermis (Bhawan et al., 1986). It is also possible that alterations of 
keratinocytes due to viral infection affect the migration of LCs to the epidermis.  
 Condyloma acuminatum is induced by human papillomavirus and is 
characterized by the proliferation of stratified squamous epithelial tissue; it affects the 
anogenital and oral mucosa (Morelli et al., 1994; Curi et al., 2017). In a study of 20 
condylomata of the vulva the intraepithelial LCs showed abnormal morphology and a 
significantly lower number density than controls. CD1a positive LCs were observed in 
the underlying dermis, suggesting an abnormal epithelial traffic of DCs. T lymphocytes 
were the main cellular infiltrate in vulvar papillomavirus infection (Morelli et al., 1994). 
A study of Giomi et al. (2011) confirmed the suitability of the treatment with 
aminolevulinic acid and photo-dynamic therapy for the treatment of condylomata and 
showed that LCs and CD4+ and CD8+ lymphocytes infiltrate heavily the underlying 
dermis in the responding patients. This seems to temper or even eliminate viral infection 
in more than half of the treated patients, generally within one month from the beginning 
of treatment. Stimulation of DCs with imidazolquinoline may be helpful in the 
treatment of condylomata in HIV infected patients (Cyru et al., 2017). 
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Dendritic cells in therapy 
 Given the role of DCs in immunity, the manipulation of skin-derived DCs has a 
potential to generate defensive immunity or for inducing tolerance in a number of 
disease conditions (Banchereau and Paluka, 2005). 
 Immunotherapy can be defined as the treatment of disease by inducing, 
enhancing or suppressing the immune response (Galluzzi et al., 2014). Immunotherapy 
can be active or passive (Lesterhuis et al., 2011). In passive immunotherapy, preformed 
antigen-targeting monoclonal antibodies or T cells endowed with intrinsic anti-target 
cell activity are transferred to the patient. In active immunotherapy, vaccines and 
checkpoint inhibitors exert effects mediated by the action of the host immune cells. DC-
based vaccines are a form of active immunotherapy (Galluzzi et al., 2014; Coosemans et 
al., 2015).  
 In recent years, there has been a growing interest towards cancer 
immunotherapy, taking advantage of the host immune system to fight cancer by 
regulating the induction of protective immunity (Steinman and Mellman, 2004; 
Banchereau and Paluka, 2005). In search of the best vaccination strategies, attention has 
been drawn also on DCs (Kantoff et al., 2010; van Dinther et al., 2017).  
 Several forms of DC-based immunotherapy have been developed, most of which 
involve the isolation of patient- or donor-derived circulating CD14+ monocytes or 
CD34+ progenitors and their amplification/differentiation ex vivo followed by 
maturation; the latter step is particularly important because immature DCs exert 
immunosuppressive, rather than immunostimulatory functions (Palucka and Banchereau 
2012). These cells can be re-infused into cancer patients upon exposure to tumour 
associated antigens (TAAs); exposure may be directly to TAA derived peptides 
(Mayordomo et al., 1995; Hirayama and Nishimura, 2016), bulk cancer cell lysates (of 
autologous or heterologous derivation) (Fields et al., 1998; Fucikova et al., 2011), bulk 
  44
cancer cell-derived mRNA (Boczkowski et al. 2000), vectors coding for one or more 
specific TAAs (Irvine et al., 2000), or mRNAs coding for one or more specific TAAs 
(Zeis et al., 2003). 
 The use of DCs in immunotherapy against cancer is still a difficult task, since 
the conditions for their activation as immune stimulating cells are still largely unclear 
and cells not properly activated may be totally ineffective to elicit a protective response 
or even counter-productive (Figdor et al., 2004).  
 Considerable clinical research has focused on improving systemic treatments for 
melanoma, that is immunogenic and, on the contrary, is generally resistant to standard 
chemotherapy after surgical excision which remains the primary treatment option. 
Complete spontaneous regression of melanoma has been observed in some patients, a 
phenomenon thought to be mediated by the immune system (Faries and Morton, 2005). 
For this reason, thirty years ago studies have started on vaccine efficacy in patients with 
metastatic melanoma, exploiting melanoma-associated antigens (Morton et al., 1989; 
Morton et al., 1992), but until now limited success has been observed in the clinics 
despite encouraging biological results (Fay et al., 2006).  
 An ex-vivo DC-based vaccine for metastatic melanoma consisting of DCs pulsed 
with autologous, ex vivo expanded tumour cells has given encouraging results (Dillman 
et al., 2004, 2009). Two recent phase I studies have also reported encouraging clinical 
results with personalized vaccines made from molecules generated by molecular 
biology and including peptides potentially attaching to patient's MHC-I and MHC-II 
molecules (Ott et al., 2017) or corresponding mRNAs (Sahin et al., 2017); mRNA can 
be uptaken by peripheral DCs and elicit an immune response in lymph nodes (Kreiter et 
al., 2010). A few patients who experienced recurrence underwent regression with anti-
PD1 therapy, which interferes with T-cell suppression by tumour cells (Hamid et al., 
2013; Ott et al., 2017; Sahin et al., 2017). This type of treatment does not directly 
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interfere with DCs, rather potentiates T lymphocytes by inhibiting the activation of PD-
1 by its ligand PD-L1, which would lead to death of CD8+ T cells. 
 
 
Nanoparticles as possible adjuvants in immunotherapy 
 Nanoparticle (NP)-based vaccines are also being studied for cancer 
immunotherapy, taking advantage of materials with at least one dimension under the 
micrometer (Park et al., 2013). Nanotechnology has drawn attention of scientists from 
many fields in the last years, prompting to technological request for high performance. 
Since nanomaterials have very different properties compared with bulk ones they are 
appealing for biomedical applications, which has led to the new branch of nanomedicine 
(Lynch and Dawson, 2008). Nanoparticles can be employed as carriers for other 
chemical species, such as fluorescent or radio-opaque or magnetic molecules for 
imaging (McDonald et al., 2017) and drugs for therapy (Park et al., 2013; Valentini et 
al., 2013; Bobo et al., 2016). They offer the possibility of a localized delivery of these 
substances, as they can be functionalized with specific receptors which allow the 
selective binding to a target tissue or organ (Ghosh et al., 2008). 
 Dendritic cells are the first cells to act in the sequence of events leading to 
immune response toward antigens, it is therefore important to understand how these 
cells interact with nanomaterials candidate to be used as regulators of the immune 
response. However, it must always be considered that the interactions of NPs with their 
biological environment depends by a complex interplay between the controllable 
properties of the particles, such as size, shape and surface chemistry, and the largely 
uncontrollable properties of the surrounding medium (Bobo et al., 2016). Particle size 
plays a key role in the clearance of these materials from the body, with small particles 
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(<10 nm) being cleared via the kidneys and larger particles (>10 nm) through the liver 
and the mononuclear-phagocyte system (Choi et al., 2007; Sadauskas et al., 2007). For 
biomedical applications, organic (Hu et al., 2004; Foerster et al., 2016 ) and inorganic 
NPs are under evaluation. Silica and gold NPs are among the most investigated 
inorganic ones (Fogli et al., 2017). Both are characterized by well-established and easy-
to-follow synthetic routes, high biocompatibility and tunable physicochemical 
properties (Walkey et al., 2012). Nanoparticles can be modified to carry an antigenic 
cargo, which can in turn be internalized together with the NP and processed for 
presentation to lymphocytes (Prasad et al., 2011; García-Vallejo et al., 2012).  
 
 
Peroxisome proliferator activated receptors (PPAR) and dendritic cells  
 
PPAR 
 A very large number of genes, cytokines, various hormones and lipids may 
influence the function and immunophenotype of DCs, contributing to lineage, subtype, 
and functional specification. Among nuclear receptors, the regulation of these cells 
depends on those for glucocorticoids, vitamin D, retinoic acid and peroxisome 
proliferator activated receptors (PPARs). The latter belong to a large group of related 
transcription factors (48 members identified in humans) referred to as the nuclear 
receptor superfamily, which can bind small lypophilic ligands that induce their 
transcriptional activities (Varga et al., 2011). PPARs play roles in an ever increasing list 
of regulatory pathways, such as those regarding lipid, lipoprotein and glucose 
metabolism, inflammation, endothelial function, cancer, atherosclerosis and bone 
morphogenesis (Reka et al., 2011; Varga et al., 2011).  
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 Three isotypes of PPAR have been identified: PPAR-α, -β (also known as δ) and 
-γ (Issemann and Green, 1990; Fajas et al., 1997). Each of these three subtypes display 
differential tissue distribution and mediate specific functions such as early development, 
cell proliferation, differentiation, apoptosis and metabolic homeostasis (Misra et al., 
2002). The three types of PPARs exhibit also different ligand affinity but share a 
common feature: upon ligand binding they form a hetrodimer with the retinoid X 
receptor (RXR) and bind to canonical peroxisome proliferator response elements 
(PPREs) that are usually located upstream of acutely regulated PPAR target genes 
(Nagasawa et al., 2009; Luconi et al., 2010). 
 PPAR-α is mainly expressed in cells with high catabolic rates of fatty acids, such 
as liver, muscle, heart and skin (Issemann and Green, 1990; Braissant et al., 1996). 
 PPAR-β/δ is ubiquitously expressed with a higher level in gut, epidermis, 
placenta, skeletal muscles and adipose tissue (Michalik et al., 2003) and plays a role in 
embryonic development and adipocyte physiology (Braissant et al., 1996).  
 PPAR-γ is highly expressed in adipose tissue and in multiple other tissues, such 
as breast, colon, lung, ovary, prostate, thyroid (Lambe and Tugwood, 1996), in the 
vascular wall (Marx et al., 1999), in cells of the immune system such as monocytes, 
macrophages and DCs - which suggests its involvement in immunity (Nencioni et al., 
2002; Asada et al., 2004) - and in hematopoietic stem cells (Greene et al., 1995). PPAR-
γ has gained medical relevance through the discovery of drugs, that are members of the 
thiazolidinedione class as pioglitazone, rosiglitazone and troglitazone (Hirakata et al., 
2004), which can be used in the clinics to improve insulin sensitivity in type 2 diabetic 
patients and are high-affinity ligands for PPAR-γ (Kliewer et al., 1995). Due to its 
importance in the treatment of type 2 diabetes and its complications, PPAR-γ is the 
most intensively studied PPAR (Varga and Nagy, 2008). 
 For certain nuclear receptors, including PPARs, the identity of their endogenous 
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ligands remains largely elusive; preliminary evidence suggests that several lipids, 
including fatty acids and their derivatives, eicosanoids and phospholipids activate target 
gene expression either directly as PPAR ligands, or indirectly as precursors for other 
lipid that ligate PPARs (Forman et al., 1997; Kliewer et al., 1997; Chakravarthy et al., 
2009; Haemmerle et al., 2011). Upon ligand binding, the nuclear receptors can activate 
or repress the transcription of a broad spectrum of genes (Mangelsdorf et al., 1995). 
 It seems that PPAR-γ binds lipophylic ligands, including unsaturated fatty acids, 
arachidonic acid metabolites 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) and 15-
HETE (hydroxyeicosatetraenoic acid), and fatty acid-derived components of oxidized 
low-density lipoproteins (oxLDL), 9- and 13-HODE (hydroxyoctadecadienoic acid); 
also, PPAR-γ covalently binds a subsets of fatty acids and can even bind two ligand 
molecules at a same time. This latter behaviour could explain why the ligand binding 
pocket of PPAR-γ is unusually large compared to that of related nuclear receptors. 
Simultaneous binding of two ligands would also support the hypothesis that PPAR-γ is 
not a specific target for one particular fatty acid but samples the intracellular mixture of 
various fatty acid molecules (Varga and Nagy 2008; Itoh et al., 2008). As a transcription 
factor, PPAR-γ directly regulates the expression of several genes participating in pre-
adipocyte differentiation, fatty acid uptake and lipid storage (Lehrke and Lazar, 2005; 
Varga and Nagy 2008) and regulates glucose homeostasis (Tontonoz et al., 1994; 
Spiegelman, 1997, 1998); moreover, it exerts anti-inflammatory actions (Cunard et al., 
2002; Nencioni et al., 2002). PPAR-γ agonists were shown to abrogate the expression of 
pro-inflammatory genes such as nitric oxide synthase (iNOS), matrix metalloproteinase 
(MMP)-9 and scavenger receptor A in murine macrophages (Ricote et al., 1998), and 
TNF-α, IL-1β and IL-6 in human monocytes (Hinz et al., 2003). The anti-inflammatory 
activity of PPAR-γ is dependent on its ability to antagonize and block the pro-
inflammatory transcription factors nuclear factor-κB (NF-κB), adaptor-related protein 
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complex 1 (AP-1) and signal transducer and activator of transcription (STAT) (Ricote et 
al., 1998; Chinetti et al., 2000; Welch et al., 2003; Celinski et al., 2011). A consequence 
is the block of the production of inflammatory cytokines by several cell types of the 
immune system (Gosset et al., 2001; Nencioni et al., 2002) 
 Among cells of the immune system, PPAR-γ is expressed in humans by 
monocytes, macrophages, mDCs and a subset of S100-positive antigen-presenting cells 
of the tonsils (Szatmari et al., 2004), and in the mouse by macrophages and mDCs, 
including LCs (Hammad et al., 2004). Both mouse and human DCs express an 
undetectable or a very low amount of PPAR-α (Gosset et al., 2001; Nencioni et al., 
2002; Szatmari et al., 2004). In contrast, the mRNA of PPAR-β has been detected in 
monocyte-derived human DCs and murine mDCs (Hammad et al., 2004; Szatmari et al., 
2004). 
 
PPAR-γ in dendritic cells  
 Dendritic cells are used as a model to investigate how the trascriptional activities 
of PPAR-γ can lead to the modulation of immune functions and some information has 
been obtained for DCs derived from peripheral blood monocytes, using PPAR-γ 
agonists (Szatmari et al., 2006; Varga and Nagy 2008). PPAR-γ agonists may be used as 
tools to address the role of these receptors in the differentiation, maturation, migration, 
cytokine production and antigen uptake and presentation by the DCs (Ahmadian et al., 
2013). It has been seen that rosiglitazone, a PPAR-γ agonist, favours the full 
differentiation of LCs from CD133+ haematopoietic precursors of the cord blood 
(Bonetti et .al, 2014). 
 The expression of PPAR-γ is induced immediately at the start of culture leading 
to differentiation of these cells and is down-regulated soon afterwards, but not 
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abolished, so that PPAR-γ is expressed at high level only in a narrow timeframe and at 
lower levels thereafter; the highest level of expression and ligand responsiveness occurs 
in the first 24 hours of culture, but after 5 days culture with a PPAR-γ agonist a change 
occurs in gene expression and consequently in phenotypic features (Varga and Nagy 
2008), as shown below.  
 Upon ligand binding PPAR-γ binds in turn to canonical PPREs upstream of 
acutely regulated PPAR-γ target genes. PPAR-γ belongs to the group of nuclear 
receptors that bind to their response elements when they form heterodimers with their 
obligate partner retinoid X receptor (RXR), a promiscuous nuclear receptor. PPAR-
γ/RXR heterodimer recruits a protein complex that consists of co-activators or co-
repressors to direct transcriptional activation or repression, respectively. The binding of 
PPAR-γ/RXR heterodimer to PPREs has been shown to result in the stimulation of 
transcription; in the absence of ligands, PPAR-γ/RXR heterodimers bind to PPREs in a 
conformation that favours the binding of co-repressor molecules leading to the 
inhibition of transcription. PPAR-γ activation by ligand binding can also lead to the 
repression of gene expression, possibly through a trans-repression mechanism (Varga 
and Nagy, 2008). Upon ligand binding, PPARγ can also interfere with the activity of 
distinct transcription factors, such as NF-κB, through protein–protein interactions 
(Pascual and Glass, 2006). 
 PPAR-γ ligands are able to alter the maturation and immunogenicity of DCs 
stimulated by specific receptors, such as TLR, by inhibiting extracellular signal-
regulated kinase (ERK), NF-κB and mitosis-activated protein (MAP)-kinase pathways 
(Appel et al., 2005; Wei-guo et al., 2010), and to impair the expression of co-timulatory 
molecules (CD83, CD80, CD40) (Szatmari et al., 2006).  
 Differentiation of DCs in the presence of a PPAR-γ agonist leads to reduced 
expression of CD1a and CD80 compared to culture without that agonist; the treatment 
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apparently does not affect the light microscopical aspect of the differentiated cells 
(Nencioni et al., 2002; Szatmari et al., 2004, 2007). PPAR-γ agonists treatment of 
differentiating DCs leads also to lower expression of CCR7, hindered migration and 
lower secretion of several cytokines, namely IL-6, IL-10, IL-12, IL-15, IFN-γ-inducible 
protein (IP)-10 also known as chemokine (C-X-C motif) ligand (CXCL)10, MCP-2, 
CCL5 also known as regulated upon activation, normal T-cell expressed and secreted 
(RANTES), EBI1 ligand chemokine (ELC) and TNF-α. These modifications indicate a 
general negative effect of PPAR-γ on the production of inflammatory cytokines by DCs 
and favours the differentiation of T cells into T-helper 2 rather than T-helper 1 
lymphocytes (Gosset et al., 2001; Nencioni et al., 2002; Szatmari et al., 2006). On the 
contrary, PPAR-γ agonist-treated monocyte-derived DCs undergo up-regulation of 
CD86 and MHC-II and express more CD1d than untreated cells. CD1d expression in 
monocytes is high and sustained throughout the differentiation process of DCs. This 
marker recognizes and presents lipid antigens to invariant NK cells, that are activated, 
proliferate and release inflammatory cytokines, as INF-γ, TNF-α, IL-4, IL-5 and MIP1-
α (Szatmari et al., 2006; Varga and Nagy 2008). DCs differentiated in the presence of 
PPAR-γ agonists have shown up-regulation also of the receptor for apoptotic cells, i.e. 
CD36 (Tontonoz et al., 1998, Gosset et al., 2001; Nencioni et al., 2002; Szatmari et al., 
2007), enhanced phagocytic activity and induced expression of a multidrug trasporter 
molecule, that confers protection against xenobiotics (Agostini et al., 2006),  
 Upon stimulation with LPS, DCs differentiated in the presence of a PPAR-γ 
agonist do not express CD1a and express CD80 and CD83 at lower levels than cells 
generated without that agonist (Nencioni et al., 2002). The effects of PPAR-γ agonists 
on differentiating DCs have been reported to be concentration dependent (Nencioni et 
al., 2002; Majai et al., 2007). 
 It is not yet clear whether these phenotypic changes are due to direct 
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transcriptional effects on inflammatory gene expression or to secondary changes 
induced in lipid metabolism (Szatmari et al., 2007). Asada et al. (2004) suggested that 
PPAR-γ modulates the gene expression of CD36 through direct interaction with the 
proximal promoter of that gene via a specific response element. The PPAR-γ agonists 
glitazones also stimulate endocytosis in immature (Szanto et al., 2004; Szatmari et al., 
2006) and mature DCs (Luo et al., 2004) and phagocytosis by immature DCs, but the 
pro-inflammatory response and the capacity to trigger T cell activation are not 
enhanced, suggesting that the functions of DCs undergo very complex regulation upon 
stimulation of PPAR-γ (Majai et al., 2010). The addition of PPAR-γ agonists during the 
generation of DCs in vitro has controversial effects on the generated cells. Nencioni et 
al. (2002) and Appel et al. (2005) reported that DCs generated in the presence of PPAR-
γ agonists had impaired T cell stimulating activity. In a mouse model of atopic 
dermatitis, PPAR-γ agonists led to decreased severity of the disease, while they 
inhibited the maturation in vitro of DCs (Jung et al., 2011). Szatmari et al. (2004) 
reported, upon PPAR-γ stimulation, a normal T cell-activating capacity of DCs and an 
increased stimulatory activity on invariant NK-T cells in the presence of galactosyl-
ceramide; the latter effect was considered dependent on increased expression of CD1d 
and glycolipid presentation through this molecule. In a later review, Szatmari et al. 
(2006) considered that PPAR-γ agonist impaired the allostimulatory capacity of DCs. 
The stimulation of PPAR-γ may also interfere with the migration of DCs out of 
peripheral tissues, indeed Nencioni et al. (2002) reported that the activation of PPAR-γ 
in DCs inhibited the expression of CCR7, a receptor involved in the localization to 
lymphoid tissue and maturation of DCs (Li et al., 2011). Using a murine model of LC 
migration induced by TNF-α, Angeli et al. (2003) found that the PPAR-γ agonist 
rosiglitazone specifically impairs the departure of those cells from the epidermis. Local 
production of PPAR-γ activators, for instance arachidonic acid derivatives, in the 
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peripheral sites during inflammatory reactions may therefore be important for the 
regulation of immune responses. In human DCs the activation of PPAR-γ also leads to 
the generation of retinoic acid, a molecule that regulates DCs phenotype and may 
concur to fine tuning the function of these cells (Szatmari et al., 2006). In particular, in 
the absence of inflammatory signals retinoids induce apoptosis of DCs, while in the 
presence of inflammatory cytokines they potentiate DC activity by increasing NF-κB 
binding to DNA, triggering the expression of MHC-II and costimulatory molecules at 
the cell surface, promoting the transition to mature DCs and leading to enhanced 
antigen-specific T cell response (Geissman et al., 2003; Szatmari et al., 2006). 
  54
Aim  
 
 Given the ability of dendritic cells to regulate the immune system and their 
essential role in inflammatory processes in response to tissue injury and in generating 
antitumor immunity, these cells are considered possible clinical targets. Also, these cells 
- depending on intrinsic properties and the microenvironment - may cause anergy or 
stimulate active tolerance; this prompts to understand how these different functions are 
regulated in order to control dendritic cell function for clinical purposes. 
 In order to better understand the steps and control mechanisms of the 
differentiation of dendritic cells, this research addresses the potentials for such 
differentiation of different precursors present in adult blood and the possible role of 
PPAR-γ stimulation on that process, given the possibility that dendritic cells, including 
Langerhans cells, express those receptor. 
 Therefore the following steps were undertaken: 
1) characterize CD14, CD34 and CD133 positive peripheral blood progenitors and 
verify the possibility to use them as starting population to differentiate dendritic cells 
and Langerhans cells; 
2) assess the steps of this differentiation and the phenotype of generated cells; 
3) using cells generated from CD14+ monocyte precursors, assess the interactions of 
dendritic cells with inorganic nanoparticles and the effects of this interaction on the 
morphological, immunophenotypical and functional properties of the cells; 
4) establish the effect of PPAR-γ stimulation on these processes, taking advantage of the 
antidiabetic drug rosiglitazone as a tool to activate those receptors; 
5) evaluate the expression of PPAR-γ with and without the stimulation of rosiglitazone, 
at different times of cell culture. 
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Materials and Methods 
 
Isolation and culture of CD14+ cells from peripheral blood  
 Human CD14+ cells were isolated from buffy coats obtained from healthy 
donors and stored at +4°C for 24 h before use, by density gradient centrifugation on 
Ficoll (Lymphoprep, Euroclone, Pero, Italy) for 15 min at 800 x g. The buffy coat was 
suspended in 2,5% dextran (Amersham Pharmacia Biotech, Sweden) in 0.9% NaCl and 
stabilized at 37°C for 30 min. Upon dilution with phosphate buffered saline pH 7.4 
mol/litre (PBS) the suspension was stratified over Ficoll and centrifuged as indicated. 
Upon washing in PBS, the CD14+ cells were selected by a magnetic field upon 
labelling with colloidal superparamagnetic microbeads conjugated with mouse anti-
human CD14 monoclonal antibody (Miltenyi Biotec, Bergisch Gladbach, Germany), 
following a previously published protocol (Miltenyi et al., 1990; Paccosi et al., 2014); 
beads were added at the cell suspension (20 µl beads per 107 total cells) and were let 
incubate at 4°C for 15 min. After wash with PBS the cell suspension was injected into 
the column for separation. After elution of unlabelled cells, the column was extracted 
from the magnet and CD14+ cells were recovered with PBS. 
 The cells were seeded at mean concentration di 1 x 106 cells/ml in RPMI 1640 
with 10% heat-inactivated foetal bovine serum (FBS), 100 U/ml penicillin and 0.1 
ng/ml streptomycin  (all from Sigma-Aldrich, St Louis, Mo, USA), GM-CSF (10 
ng/ml), IL-4 (10 ng/ml), TNF-α (10 ng/ml) and TGF-β (10 ng/ml) for 7 days, thus 
obtaining immature DCs; final maturation was induced with the same cytokines plus IL-
1β (10 ng/ml), IL-6 (1000 U/ml) and TGF-β (20 ng/ml) for additional 24 h. All 
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cytokines were purchased from PeproTech. For TGF-β the isoform 3 was used: the 
three isoforms of TGF-β signal through the same receptor and elicit similar biological 
responses (Sporn and Roberts, 1992). 
 The isolated cells from each donor were split and seeded with and without 
rosiglitazone (Selleckchem, TX). The same was done also for the culture of the other 
precursors indicated below. For all precursors, each donor was used alone for one 
experiment. 
 Rosiglitazone (1 µmol/l, i.e. 0.36 µg/ml) was added since the start of culture; 
culture without rosiglitazone was used as control. The drug was obtained from the 
producer as a powder and was dissolved in dimethyl sulfoxide at a concentration of 100 
mmol/l for storage. It was then diluted in 0.1% bovine serum albumin (BSA) down to 
100 µmol/l before adding to the culture medium at the indicated final concentration. 
 
Isolation and culture of CD34+ cells  
 Human CD34+ cells from healthy donors were isolated from freshly recovered 
buffy coats. The mononuclear cells were isolated by Ficoll density gradient 
centrifugation and were washed in phosphate buffered saline, pH 7.4 (PBS) with 1% 
FBS. Up to 108 cells were resuspended in a final volume of 300 µl PBS and labelled 
with superparamagnetic microbeads conjugated to mouse anti-human CD34 monoclonal 
antibodies for 30 min at 4° C, according to the producer instructions (Microbeads 
UltraPure, human, Miltenyi Biotec). The cell suspension was loaded onto a MACS 
Column (Miltenyi) which was placed in the magnetic field MACS Separator (Miltenyi). 
The magnetically labelled CD34+ cells are retained within the column while the 
unlabeled cells run through. After removing the column from the magnetic field, the 
CD34+ cells were eluted and counted. 
  57
 Purified CD34+ cells (500,000 cells/ml) were seeded in RPMI 1640 with 10% 
FBS, 100 U/ml penicillin and 0.1 ng/ml streptomycin and cultivated for 7 days with 
SCF (20 ng/ml), TPO (10 ng/ml), Flt3-L (25 ng/ml), GM-CSF (10 ng/ml), IL-4 (10 
ng/ml), TGF-β (10 ng/ml) (all from Peprotech). The culture was further continued for 7 
more days with GM-CSF, IL-4, TNF-α and TGF-β, at the same concentrations indicated 
above for CD14+ cells. For last additional four days, i.e. from day 14 to day 18 of 
culture, TGF-β concentration was raised to 20 ng/ml and IL-1β (10 ng/ml) and IL-6 
(1000 U/ml) were added, while GM-CSF, IL-4 and TNF-α, were maintained at the same 
concentration indicated above (Tab. 1). 
Table 1 - Cytokines used for culture of CD34+ and of CD133+ precursors. 
Concentrations are ng/ml. 
  0 -7 d 7 - 14 d 14 - 18 d 
TPO 10   
FLT-3 25   
SCF 20   
GM-CSF 10 10 10 
IL-4 10 10 10 
TNF-alpha 10 10 10 
TGF-beta  10 10 20 
IL-1 beta   10 
IL-6   15 
 
 Rosiglitazone (1 µmol/l, i.e. 0.36 µg/ml) was added since the start of culture in 
some experiments, as specified above. 
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Isolation and culture of CD133+ cells from peripheral blood 
 Human CD133+ cells were isolated from fresh buffy coats. The mononuclear 
cells were isolated by Ficoll density gradient centrifugation, the cells were washed in 
PBS, and resuspended in a final volume of 200 µl PBS for up to 5 x 107 cells, following 
the indications of the producer (Diamond CD133 isolation kit, human, Miltenyi Biotec), 
The cells were incubated with a cocktail of biotin-conjugated mouse monoclonal 
antibodies against human CD2, CD3, CD11b, CD14, CD15, CD16, CD19, CD56, CD61 
and CD253a, for 10 min at 4° C, washed in PBS and resuspended in 400 µl PBS. Anti-
biotin microbeads were added for 15 min. at 4° C, then the cell suspension was loaded 
onto a MACS Column placed in the magnetic field MACS Separator (all from Miltenyi) 
so that the magnetically tagged cells were retained within the column while the 
unlabelled ones passed through. The unlabelled, effluent cells were washed and 
resuspended in 200 µl PBS (up to 5 x 107 per sample), adding 50 µl of micro beads 
conjugated with monoclonal CD133 antibodies for 30 min at 4° C. Upon subsequent 
magnetic separation the CD133+ cells and subsequent elution of the retained cells, the 
latter were placed in culture with the same cytokines for the same times indicated for 
CD34+ cell culture.  
 
Isolation of lymphocytes for mixed lymphocyte reaction 
 Allogeneic lymphocytes were recovered from buffy coats - obtained from 
healthy donors and stored at +4°C for 24 h before use - by density gradient 
centrifugation on Ficoll, as above. The cells were washed in PBS and seeded in RPMI 
10% FBS for 45 min. Non-adherent cells were collected and were centrifuged at 160 x 
g, for 10 min at 20°C, counted and used for mixed lymphocyte reaction (MLR). 
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Analysis of in vitro generated dendritic cells 
 At the end of culture the morphology, the immunophenotype and lymphocyte-
stimulating activity of the generated cells were analysed by immunofluorescence, flow 
cytometry, electron microscopy and mixed lymphocyte reaction. 
 The same methods were used to evaluate the interaction of DCs (obtained from 
CD14+ cells) with NPs. 
 Also, the expression of the PPAR-γ by the cells grown with and without 
rosiglitazone (not treated with NPs) was evaluated at different times from the start of 
culture (0, 7, 14 and 18 days) by quantitative real-time polymerase chain reaction (qRT-
PCR). 
 
Immunofluorescence 
 Double immunofluorescence analyses were performed on cytospins of mature 
DCs, that were fixed with cold acetone for 3-5 min at room temperature. After blocking 
non-specific binding sites with 10 ng/mL BSA (Sigma-Aldrich) in PBS with the 
addition of 0.5% triton X-100 (Sigma, Milan, Italy) for 30 min at room temperature, 
primary antibodies (anti-human) were applied over night at 4°C at the indicated 
dilutions. The following antigens were tagged first: ICAM-1/ CD54 (Merck  Millipore, 
Darmstadt, Germany; monoclonal mouse IgG1, 1:50), langerin/CD207 (Dendritics, 
Lyon, France; mouse monoclonal IgG1, 1:50), DC-SIGN/CD209 (Sigma-Aldrich; 
rabbit polyclonal, 1:50). Secondary goat anti-mouse and anti-rabbit polyclonal 
antibodies conjugated with Alexa Fluor AF594 (red fluorescence), all from Life 
Technology (Thermo Fisher Scientific, Waltham, MA), were applied for 2 hours at 
room temperature. Afterwards, fluorescein isothiocyanate (FITC) conjugated anti-
human HLA-DR sntibody (Miltenyi Biotec, mouse monoclonal IgG2aκ, 1:20) was 
added over night at 4°C. The signal was amplified with anti-FITC goat polyclonal 
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antibody conjugated with AF488 (green fluorescence; Thermo Fisher Scientific; 1:100). 
Nuclei were labelled with Hoechst 33342 (20 µg/mL; Sigma). Omission of primary 
antibodies or substitution with irrelevant ones were used as negative controls. 
 The slides were mounted with Gel/Mount (Fluoromount, Diagnostic 
BioSystems, Pleasanton, CA), observed in an Axioskop microscope equipped for 
epifluorescence (Zeiss, Oberkochen, Germany) and captured with an Axio Vision 4 
system, consisting of a digital multichannel fluorescence module and dedicated software 
(Zeiss), or observed in a DMR HC microscope equipped for epifluorescence (Leica 
Microsystems GmbH, Wetzlar, Germany). 
 
Flow Cytometry  
 For some samples fixation and permeabilization were performed to evaluate 
intracytoplasmic langerin/CD207 expression, using the cell permeabilization kit of 
Nordic-Mubio (Susteren, Netherlands) according to the directions of the manufacturer. 
The indicated amounts of the following monoclonal antibody solutions were added to 
100 µl of cell suspension containing 10,000-60,000 cells, as suggested by the producer: 
5 µl HLA-DR-Horizon violet (HV450) or 7.5 µl HLA-DR-FITC (BD Biosciences, 
Franklin Lakes, NJ), 6.5 µl CD1a-phycoerythrin (PE) (BD Biosciences), 6.5 µl CD11c--
allophycocyanin (APC) H7 or CD11c-PE (BD Bioscience), 5 µl CD14-APC (BD 
Biosciences), 5 µl CD33-phycoerythrin with cyanine dye Cy7 (PeCy7), 5 µl CD34-
peridinin chlorophyll protein with the cyanine dye Cy5.5 (PerCP-Cy 5.5) (BD 
Biosciences), 7.5 µl CD45-FITC or 5 µl CD45-HV450 (BD Bioscience), 7.5 µl CD80-
FITC (Miltenyi Biotec), 6.5 µl CD83-PE, 6.5 µl CD86-PE or 5 µl CD86-APC (BD 
Bioscience), 10 µl langerin/CD207-APC (Miltenyi Biotec). The cells were immuno-
labelled for 15 min at room temperature, protected from the light. Dead cells were 
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counted by flow cytometry upon labelling with 7-amino-actinomicin D (BD 
Biosciences). 7-aminoactinomycin D (AAD) was used to recognize dead cells and 
exclude them from analysis. Isotype-matched antibodies were used as negative controls. 
 Flow cytometry was performed by collecting more than 10,000 events on a 
FACSCanto II (Becton Dickinson, Sparks, MD) and data were analysed with Infinicyt 
1.7 (Citognos, Salamanca, Spain). 
 
Electron microscopy  
 Cell pellets were fixed in 2% formaldehyde and 2.5% glutaraldehyde in 0.1 
mol/L cacodylate buffer, pH 7.4, osmicated and embedded in epoxy resin. Sections 
were stained with gadolinium acetate (Electron Microscopy Sciences, Hatfield, PA; 
Nakakoshi et al., 2011) and either lead citrate or bismuth subnitrate (Riva, 1974), and 
observed in a Jeol JEM 1010 electron microscope (Tokyo, Japan) at 80 kV. 
Photomicrographs were taken with a digital camera MegaView III (Soft Imaging 
System, Muenster, Germany) connected with a personal computer (Dell, Round Rock, 
TX) with dedicated software (AnalySIS, Soft Imaging Software, Muenster, Germany). 
 
Mixed lymphocyte reaction  
 Lymphocytes were stained with the fluorescent dye carboxyfluorescein 
succinimidyl ester (CFSE) following manufacturer instructions. 2x105 lymphocytes 
were cultured 5 days in complete medium with 4x104 DCs. Mature DCs generated at the 
end of incubation period from different precursors and immature, monocyte derived 
DCs pre-incubated with NPs were subjected to this analysis. Lymphocytes stimulated 
with 5 µg/ml phytohaemoagglutinin (PHA, Biochrom, MA) were used as positive 
controls. After 5 d lymphocytes were recovered and stained with fluorescent mouse 
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monoclonal antibodies following manufacturer’s instructions: anti-CD3-PerCP-Cy5.5, 
anti-CD4-PE and anti-CD8-APC (BD Bioscience).  
 
Gene expression 
 The expression of PPAR-γ was evaluated by quantitative qRT-PCR using Cells-
to-CT 1-Step TaqMan Kit (Thermo Fisher Scientific), that allows to measure relative 
gene expression by qRT-PCR analysis directly from cultured cells, without preliminary 
RNA purification and amplification. The lysis technology is designed for 10–100,000 
cultured cells per sample, thus for each assay ~80,000 cells were washed in PBS, 
counted and lysed for 5 min at room temperature; genomic DNA was simultaneously 
removed with DNase. Lysis was terminated at room temperature by 2 min incubation 
with Stop Solution. The lysate was mixed with TaqMan® 1-Step qRT-PCR Mix 
(Thermo Fisher Scientific) and with TaqMan® Gene Expression Assays for PPAR-γ 
and GAPDH housekeeping gene (Applied Biosystems for Thermo Fisher Scientific), at 
the volumes indicated by the producer. The results were read in a Rotor-Gene Q 
(Qiagen, Germany) with the following settings: 1 cycle of reverse trascription at 50°C 
for 5 min, 1 cycle of reverse trascription inactivation/initial denaturation at 95°C for 20 
seconds, 40 cycles of amplification at 95°C for 15 seconds and at 60°C for 1 minute. 
For the acquisition we have used Rotor-Gene Q series software. A lysate of human pre-
adipocytes was used as positive control for PPAR-γ 
 
Synthesis of NPs 
 Gold and silica NPs (AuNPs and SiO2NPs respectively) were synthesized from a 
collaborating research group at the Department of Chemistry “Ugo Schiff” of the 
University of Florence, directed by Prof. Debora Berti. Briefly, according to established 
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protocols (Turkevich et al., 1951; Stöber et al., 1968; Frens, 1973;) Rhodamine B 
isothiocyanate was added to produce fluorescent SiO2NPs. 
 
Dendritic cell culture with nanoparticles 
 Nanoparticles were added to cultures of immature DCs, obtained from CD14+ 
peripheral blood mononuclear cells as described above. NPs were added for 48 h at 
concentrations of 10 and 100 µg/mL, while the concentration of FBS was reduced to 1% 
to minimize a possible influence of serum factors on DC maturation. In some 
experiments maturation-inducing cytokines, i.e. IL-1β, IL-6, TNF-α, at the 
concentrations indicated above, were added together with NPs. Cells were checked by 
phase contrast microscopy throughout culture.  
 The DCs cultivated with NPs were analysed by fluorescence microscopy, flow 
cytometry and electron microscopy. In particular, to follow the incorporation of 
fluorescent silica NPs, for each experiment and experimental condition a drop of culture 
medium containing about 100 unfixed cells was transferred to a microscopic slide, 
covered with a coverslip and observed and photographed as detailed above. The number 
of unlabelled and that of labelled cells were counted and the percentage of labelled cells 
per slide was computed. Among labelled cells, the intensity of fluorescence was 
measured with ImageJ for Windows (NIH, Bethesda, MD): each labelled cell was 
outlined by hand and the software was used to measure the surface area (in square pixel, 
pixel size 0.0256 µm2) and the mean labeling intensity (in arbitrary units, maximum 
intensity = 255) of the cell. The two measures were multiplied for each other to obtain 
the total labeling per labelled cell. 
 The immunophenotype of DCs exposed to NPs was evaluated by flow cytometry 
for CD80, CD83 and CD86 (BD Biosciences) as indicated above. The results were read 
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in a FACSCanto II (BD Biosciences) and analysed by FACs Diva software (BD 
Biosciences). 
 The capacity of DCs challenged with NPs to stimulate lymphocytes was 
evaluated by MLR as indicated above. 
 
Statistics  
 Quantitative data were expressed as mean ± standard error (SE) and analyzed as 
appropriate by ANOVA and Student t-test for paired data. Values of p<0.05, p<0.01 and 
p<0.001 were recorded separately and assumed as significant. 
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Results 
 
Cell culture 
 Most cells obtained from CD14+ precursors showed a dendritic morphology 
after 7 days, with or without rosiglitazone (fig. 1). Some DCs obtained from CD34+ and 
CD133+ precursors acquired a dendritic morphology between 7 and 14 days, whether 
with or without rosiglitazone (figs. 2, 3). Non-dendritic cells had a round shape and 
were smaller than dendritic ones. Vitality was not affected by the addition of 
rosiglitazone to the culture medium.  
 The cell number at the start of culture was variable, it was possible to isolate 
more than 107 CD14+ cells, while one could isolate about 6x105-1.5x106 CD34+ or 
CD133+ cells. 
 The cell mortality at the end of culture was different, depending on the cell type 
of origin. The mortality of the cells obtained from CD14+ precursors was ~25%, that of 
the cells obtained from CD34+ and from CD133+ precursors was ~40%.  
 
Immunofluorescence  
 At immunofluorescence, DCs generated from CD14+ monocytes were positive 
for HLA-DR and DC-SIGN; a faint positivity for langerin/CD207 was observed in a 
few cells (fig. 4). 
At immunofluorescence almost all mature DCs from CD34+ and CD133+ precursors 
expressed HLA-DR with intensity from moderate to bright, both with and without 
rosiglitazone (figs. 5 and 6, left panels). Part of the cells obtained at the end of 
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the culture expressed CD54 (figs. 5 and 6, upper middle panels); the fluorescence 
intensity of the analyzed cells ranged from light to moderate, whether with or without 
rosiglitazone, and was most intense in paranuclear position. All cells with a larger size 
were langerin/CD207 positive (figs. 5 and 6, central middle panels), the fluorescence 
appeared in part granular; the signal ranged from light to bright and did not appear to 
vary depending on rosiglitazone addition. Most cells expressed DC-SIGN, with a light 
to bright signal apparently not affected by rosiglitazone (figs. 5 and 6, bottom middle 
panels). 
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Flow cytometry 
 
Dendritic cells from CD14+ precursors 
 Dendritic cells obtained from CD14+ precursors were analyzed in the immature 
and mature state; in both conditions they were HLA-DR+, whether with or without 
rosiglitazone. The cells were homogeneous for scatter parameters (both forward and side 
scatter). About a half of the HLA-DR+ cells expressed CD1a, in similar percentage 
before and after induction of maturation and with or without rosiglitazone.  
 The percentage of DCs expressing CD207 was slightly higher among immature 
than mature cells both with and without rosiglitazone. After permeabilization the 
percentage of DCs expressing CD207 increased over that of unfixed, non-permeabilized 
cells (fig. 7). The observed differences were not significant. 
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Dendritic cells from CD34+ precursors 
 The cells obtained from CD34+ precursors could be divided into two 
populations, one CD33+ CD45+ and the other CD33- CD45+. This latter population 
was excluded from analysis, because the lack of CD33 prevented to identify those cells 
as DCs: they represented up to 30-40% cells at the end of culture, as estimated by flow 
cytometry. Two distinct populations were observed among CD33+ CD45+ cells, which 
differed in size and cellular complexity. The latter is representative of both cell surface 
roughness and cytoplasm compartmentalization. The cells with greatest size and 
complexity were CD1a+ and CD207+. The antigen expression of DCs differentiated 
from CD34+ precursors precursors is reported in figs. 8, 9 and in fig. 10, it varied 
among donors for several antigens. 
 From any donor, all DCs obtained from CD34+ cells were HLA-DR+. Between 
50% and 70% of these cells were classified as LC like on the basis of scatter parameters 
(high forward scatter and high sid scatter). The majority of the latter cells were CD1a+ 
and almost a half were also CD207+. Rosiglitazone led to increase - but insignificantly - 
the cells expressing langerin/CD207 on the cell surface (i.e., labelled unfixed) and led to 
increase the cells labelled for CD207 upon fixation and permeabilization (fig. 10B). A 
high percentage of LC-like cells expressed CD11c, lower but far from negligeable 
percentages were found for the maturation marker CD83 and the co-stimulatory 
molecule CD80 (fig. 10A, C). A part of DCs and of LC-like cells expressed CD209. No 
significant differences were observed depending on the presence or absence of 
rosiglitazone. 
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Dendritic cells from CD133+ precursors 
 Also the DCs obtained from CD133+ precursors could be divided into a CD33+ 
CD45+ and a CD33- CD45+ population and only the first one (about 60-70% harvested 
cells) was subjected to further analysis. They were all HLA-DR+; 53-94% cells were 
LC-like, both with and without rosiglitazone, as appreciated by scatter parameters and 
the expression of CD1a and CD207 (figs. 11, 12). The percentage of cells expressing 
CD207+ was significantly higher among cells grown with than without rosiglitazone; 
this was true for both membrane and total (i.e. including intracytoplasmic) labelling; the 
amount of cells labelled upon permeabilization was not higher than that of cells labelled 
without fixation nor permeabilization. All LC-like cells expressed CD11c and the vast 
majority expressed the maturation marker CD83 and the co-stimulatory molecule 
CD80; a considerable percentage of DCs and LCs expresses DC-SIGN; no significant 
differences were observed for these molecules depending on the presence or absence of 
rosiglitazone (fig. 13).  
 The difference in the expression of CD80 between cells obtained from CD34+ 
and from CD133+ precursors was significant, the higher expression being by cells 
obtained from CD133+ cells, with or without rosiglitazone. 
 
  78
 
  79
 
  80
 
 
  81
Gene expression 
 PPAR-γ gene expression differed greatly depending on donor and precursor cell 
type, while no significant differences were found between cells grown with or without 
rosiglitazone. 
 Newly isolated CD14+ cells expressed a low number of copies of PPAR-γ 
mRNA. The expression increased during culture, with a maximum after maturation i.e. 
9 days culture (fig. 14A). 
 Freshly isolated CD34+ precursors showed a much lower expression of PPAR-γ 
gene than CD14+ cells and the expression remained low for all the culture time (fig. 
14B). 
 Also freshly isolated CD133+ precursors showed a low number of PPAR-γ 
mRNA copies, but higher than that observed for both CD14+ and CD34+ cells. This 
number increased with culture, variably among experiments i.e. donors; the response to 
rosiglitazone varied greatly with donors, the mRNA increased in the first 14 d of culture 
in three experiments and did not increase in two experiments (fig. 14C). In all but one 
experiments, i.e. with four donors, the expression of PPAR-γ mRNA upon 7 d culture 
was higher than that of newly isolated CD14+ cells. 
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Electron microscopy 
 Upon culture of CD14+ precursors, i.e. monocytes, immature dendritic cells 
were characterized by large size, dendritic shape, nucleus with shallow indentations, 
loose chromatin with small peripheral clumps, many mitochondria, well developed 
rough and smooth endoplasmic reticulum, variably extended Golgi apparatus and a few 
lysosomes. Upon maturation, dense chromatin restricted to a thin, uniform peripheral 
rim, and the cytoplasm came to contain many lysosomes appearing as electron dense, 
round bodies and thin curved cisternae with electron dense content, sometimes with 
cylindrical shape (figs. 15 to 18). 
 Upon culture of CD34+ and of CD133+ precursors, including a final maturation 
step, the harvested cells included large, dendritic cells; medium size, mildly dendritic 
cells; and small, roundish cells. The largest cells, in particular, had and oval nucleus 
with multiple, usually hollow, occasionally deep indentations, and a uniformly 
dispersed chromatin; they contained many mitochondria, well developed rough and 
smooth endoplasmic reticulum, extended Golgi apparatus, and lysosomes. The 
intermediate sized cells also had an oval nucleus, with deep indentations, and many, 
small, uniformly distributed clumps of chromatin besides an irregular peripheral rim of 
condensed chromatin. They contained several mitochondria, little rough and abundant 
smooth endoplasmic reticulum, a small Golgi apparatus and a few lysosomes. The 
smallest cells had a round, lightly scalloped nucleus, with huge clumps of dense 
chromatin both attached to the nuclear envelope and free in the nucleoplasm; the 
cytoplasm was poor in organelles, but for many free ribosomes (figs. 19 to 24). 
 Addition of rosiglitazone to culture led to modifications of the nucleus and 
cytoplasm of large dendritic cells, in that the condensed peripheral chromatin appeared 
as a thin uniform rim instead of small clumps and the cytoplsm was enriched in many 
lysosomes appearing as electron dense, round bodies and in thin, curved cisternae with 
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electron dense content, sometimes with cylindrical shape. Some cells also contained 
wide lysosomes with inhomogeneous content sometimes including recognizable 
remnants of organelles, hence expressing auto- or heterophagocytosis. These 
modifications were seen also in immature dendritic cells generated from CD14+ 
precursors. 
 Straight, short structures with parallel membranes and a fain, unstructured 
central density, as wide as Birbeck granules, were recognized occasionally in large 
dendritic cells in all culture conditions (figs. 16C, 24A). 
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Mixed lymphocyte reaction 
 The proliferation of CD4+ lymphocytes after 5 d co-culture with DCs was 
significantly higher from that of lymphocytes alone. The proliferation was significantly 
higher if the DCs had been treated without rosiglitazone during differentiation and 
maturation than if they had been grown with rosiglitazone. The measure of proliferation 
by dilution of CFSE allows to separate the response of different subtypes of 
lymphocytes. This led to recognize that the proliferative response of CD8+ lymphocytes 
to DCs was much lower than that of CD4+ lymphocytes; it appeared less marked when 
DCs had been differentiated in the presence of rosiglitazone but the difference was not 
significant, possibly because of the low numbers of proliferating cells in either 
condition (figs. 25, 26). 
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Interaction of nanoparticles with dendritic cells generated from CD14+ monocytes 
 About one third immature DCs (29-38%) had internalized 10 µg/ml fluorescent 
silica NPs after 4 e 24 h of incubation, the percentage of immature DCs internalizing 
fluorescent NPs raised to 94-98% upon incubation with 100 µg/ml fluorescent NPs. At 
each time point, the difference between NP concentrations was significant, while those 
between time points for each concentration were not significant (figs. 27A, 28). 
 Also the mean fluorescent intensity per labelled cell was significantly higher 
upon incubation with 100 µg/ml than with 10 µg/ml NPs; this intensity increased 
significantly between 4 and 24 h incubation with 10 µg/ml NPs, while it remained stable 
(at high values) upon incubation with 100 µg/ml (figs. 27B, 28). 
 Electron microscopy showed that addition of gold or silica nanoparticles led to 
their endocytosis and to the appearance of NPs within membrane-bound compartments, 
made of both small endocytic vesicles and larger structures with features of endosomes 
and lysosomes (figs. 29, 30). 
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 The immunophenotype of immature DCs incubated with SiO2NPs and AuNPs 
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(10 µg/ml and 100 µg/ml) was compared with that of untreated immature DCs (negative 
control) and of DCs stimulated with maturation-inducing cytokines (positive control). 
The results showed that NPs did not influence maturation markers expression of DCs, 
except for CD86 which was significantly increased only following 100 µg/ml AuNPs 
(23 ± 8% and 66 ± 8% for DCs without NPs and DCs with 100 µg/ml AuNPs, 
respectively) (fig. 31). 
 Dendritic cells treated with SiO2NPs or AuNPs did not stimulate lymphocyte 
proliferation significantly, at variance with DCs maturated with inflammatory cytokines 
(fig. 32). 
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Discussion 
 
 The results of this study have shown that it is possible to generate DCs from 
different precursors obtained from adult human blood. The generated progeny included 
cells with features of a specific DC type, i.e. LCs; the percentage of this last cell type 
varied depending of the precursors. The generated cells were able to stimulate mixed 
lymphocyte reaction, hence they were functionally efficient. The PPAR-γ agonist 
rosiglitazone influenced the morphology and immunophenotype of DCs, apparently 
leading to more mature features, but appeared to reduce the capacity of DCs to stimulate 
MLR when DCs were generated from a specific precursor, namely CD133+ cells which 
are believed to be the most immature among the tested cells. CD133+ precursors 
expressed mRNA for PPAR-γ at appreciable level, indeed they were the precursors 
better endowed with this mRNA among those studied here. 
 Large DCs with mature features at electron microscopy, i.e. rich in organelles 
and especially lysosomes, contained inclusions resembling Birbeck granules but with a 
rudimentary central density. Moreover, they contained flat, curved cisternae that were 
delimited by parallel membranes, had a central density over most of there extension, 
and were slightly dilated and with uniform electron dense content in some areas. The 
images resemble those of extended Birbeck granules elicited by anti-CD1a treatment of 
human epidermal LCs (Hanau et al., 1988). 
 At variance with what is usually observed in vivo, the cells with LC features, 
namely a typical scatter pattern at flow cytometry, the expression of CD1a and 
langerin/CD207 at immunophenotypical analysis, and cytoplasmic inclusions similar to 
Birbeck granules as above described, also expressed DC-SIGN/CD209 which instead is 
typical of connective tissue, non-Langerhans DCs (Nestle et al., 1993; Palucka and 
Banchereau, 2012; Klechevsky and Banchereau, 2013). This was true whichever the 
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starting precursor and suggest that the culture conditions cannot reproduce completely 
those occurring in vivo. 
 Most if not all cells identifiable as LCs, or at least LCs-like, expressed 
langerin/CD207 at the cell surface as well as in the cytoplasm, since the number of 
those cells was not appreciably increased by cell permeabilization, as estimated by flow 
cytometry. Immunocytochemistry confirmed the presence of a labelled granular 
compartment within langerin/CD207 expressing cells, as expected (Romani et al., 
2003). In DCs generated from CD34+ precursors in the presence of rosiglitazone, the 
number of cells expressing langerin/CD207 was higher upon labelling of fixed, 
permeabilized cells than unfixed cells, which suggests higher intracellular than 
membrane localization of this adhesive molecule in such cells, possibly correlated to its 
cycling through different compartments, and an influence of PPAR-γ stimulation on that 
cycling. 
 The small number of cells with LC-like features starting from CD14+ precursors 
is in substantial agreement with literature reports that LCs are not, or only in limited 
measure generated from CD14+ monocytes (Geissmann et al., 1998). Also in line with 
previous reports (Szatmari et al., 2004; Varga and Nagy 2008) is the appearance of 
PPAR-γ mRNA in cells generated from CD14+ precursors, more intensely if the culture 
was treated with rosiglitazone which hints to a possible positive feedback. Connective 
tissue cells (and also keratinocytes) can indeed secrete molecules acting as PPAR-γ 
stimulants in vivo (Kozak et al., 2002; Nakahigashi et al., 2012; Frolov et al., 2013; 
Itaka et al., 2015; Mashima and Okuyama, 2015; Powell and Rokach, 2015; Han et al., 
2017; Moore and Pidgeon, 2017) and so regulate final differentiation and function of 
DCs.  
 Treatment of CD133+ cells with rosiglitazone during culture led to the 
generation of many cells, only some which with features of LCs. In previous study from 
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this laboratory on CD133+ cells from cord blood it had been found that a small number 
of well differentiated LCs were generated while other cell types degenerated into 
detritus (Bonetti et al., 2014). Therefore the  results upon culture of CD133+ precursors 
from adult blood were in part at variance with those obtained in same laboratory starting 
from CD133+ precursors of cord blood. It is not possible exclude that this depends on 
technical reasons because in the meantime from previous research the cytokines have 
been bought new, hence they were from different lots and in some cases different 
producers, and also rosiglitazone had to be obtained new, from a different producer. 
However, it is reasonable to conceive that the differentiation potential and response to 
PPAR-γ agonists differ between foetus and adult.  
 The effect of rosiglitazone on the differentiation of DCs appeared contradictory: 
it stimulated the morphological and immunophenotipical differentiation and reduced the 
MLR stimulating ability of the generated DCs. The possibility that this depended on 
piggyback transfer of rosiglitazone to lymphocytes by DCs is highly improbable 
because DCs were extensively washed before transferring into co-culture wells for 
MLR. In this study, the effect of rosiglitazone during DC differentiation was evaluated 
for cells derived from CD133+ precursors. It had already been demonstrated by 
Nencioni (2002) and Appel (2005) that DCs generated from CD14+ precursors in the 
presence of PPAR-γ agonists had impaired T cell stimulating activity. It may be 
correlated with this effect of PPAR-γ stimulation the fact that in a mouse model of 
atopic dermatitis PPAR-γ agonists led to decreased severity of the disease and to 
selective inhibition of the maturation in vitro of DCs derived from untreated animals 
(Jung et al., 2011). 
 The study of the differentiation and functional potential of different DCs 
precursors was extended to check the interaction of DCs derived from CD14+ 
precursors with inorganic NPs. These DCs were chosen because they are quicker to 
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differentiate, require lower amounts of cytokines and can be generated from more 
numerous precursors, given the frequency of CD14+ cells in peripheral blood. Gold and 
silica NPs entered cells by endocytosis, accumulated in vacuolar (endo-lysosomal) 
compartments in the cytoplasm and did not appear to influence DC maturation except 
for a minor effect of AuNPs (these results were object of a publication: Fogli et al., 
2017). The results indicate that NPs are well tolerated by DCs and can represent a 
simple, cost-effective, easy to synthesize and effective method to deliver active 
molecules (including antigens and drugs) to DCs in view of cancer and immune-
mediated diseases therapy. However the final destiny of NPs, which are not digested by 
cell enzymes, requires further studies.  
 During this study a reason of trouble was the high variability of the results 
among experiments. For each experiments a single donor was used and each donor 
contributed to only one experiment. On account of the Italian law on privacy and 
personal data protection no information was available on the donors (not even sex or 
age), the only information being that they were healthy subjects acceptable as blood 
donors for transfusion. This drawback is intrinsic to studies with human cells and it 
could not be avoided in this research either.  
 The use of CFSE for evaluating the proliferation of the lymphocytes in MLR 
allowed to recognize a different effect of DCs generated in vitro on CD4+ and CD8+ 
lymphocytes, when DCs were generated from CD133+ precursors: these cells 
stimulated CD4+ lymphocytes, but were virtually ineffective on CD8+ lymphocytes, at 
variance with what was found for DCs generated from CD14+ cells, as shown in fig. 32: 
mature DCs not exposed to NPs and used as control for NP experiments stimulated the 
proliferation of both CD4+ and CD8+ lymphocytes. Since the cells generated from 
CD133+ precursors were more similar to LCs than those generated from CD14+ 
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precursors, the finding may indicate a different capacity of different types of DCs to 
interact productively with different subsets of T lymphocytes.  
 Dendritic cells play a important role in the immune system, in fact they 
recognize, bind and process antigens and present them to T cells to initiate an immune 
response; they cells also can cause anergy and trigger active tolerance. Despite the fact 
that DCs have been studied over years, many points regarding their differentiation and 
function remain obscure. This study has shown that the DCs can be generated in vitro 
from different precursors, that the choice of precursors influences the phenotype and 
functional ability of the generated DCs, and that the features of generated cells do not 
mach exactly those of cells seen in vivo especially LCs.  
 These findings may be relevant to the question whether, to induce, enhance or 
alternatively lower an immune response, it would be better to differentiate dendritic 
cells from haematopoietic precursors in vitro and inject them into a patient upon 
appropriate treatment, or find ways to influence the DCs of a patient in vivo, as also 
proposed in the clinics (Gerlini et al., 2012b). The latter strategy would obviate the 
imperfect control of the differentiation of DCs in vitro and the risk of raising cells prone 
to induce responses inappropriate to the single case which they would be supposed to 
cure. 
  110
Acknowledgements 
The authors gratefully acknowledge Dr Stefano Bacci, Dr. Paola Di Gennaro and Dr. 
Sergio Fabbri for advice on cell and molecular biology techniques; Mrs. Laura Calosi, 
Mr. Daniele Guasti and Mr. Stefano Catarinicchia for technical help in microscopic 
analyses; ,Associazione Italiana contro le Leucemie-Linfomi e Mieloma and the 
University of Florence for financial support. 
  111
References 
 
Ackerman A.L., Cresswell P. Cellular mechanisms governing cross-presentation of 
exogenus antigens. Nat. Immunol. 5: 678-684, 2004. 
Agostini M., Schoenmakers E., Mitchell C., Szatmari I., Savage D., Smith A., 
Rajanayagam O., Semple R., Luan J., Bath L., Zalin A., Labib M., Kumar S., Simpson 
H., Blom D., Marais D., Schwabe J., Barroso I., Trembath R., Wareham N., Nagy L., 
Gurnell M., O'Rahilly S., Chatterjee K. Non-DNA binding, dominant-negative, human 
PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab. 4: 303-
311, 2006. 
Ahmadian M., Suh J.M., Hah N., Liddle C., Atkins A.R., Downes M., Evans R.M. 
PPARγ signaling and metabolism: the good, the bad and the future. Nat. Med. 19: 557-
566, 2013. 
Ahmed Z., Kawamura T., Shimada S., Piguet V. The role of human dendritic cells in 
HIV-1 infection. J. Invest. Dermatol. 135: 1225-1233, 2015. 
Ahn S.B., Lee S.B., Singh T.D., Cho S.J., Kim S.K., Lee I.K., Jeong S.Y., Ahn B.C., 
Lee J., Lee S.W., Jeon Y.H. Multimodality Imaging of Bone Marrow-Derived 
Dendritic Cell Migration and Antitumor Immunity. Transl. Oncol. 10: 262-270, 2017. 
Albert M.L., Pearce S.F., Francisco L.M., Sauter B., Roy P., Silverstein R.L., Bhardwaj 
N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, 
and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188: 1359-1368, 
1998. 
Amigorena S., Lankar D., Briken V., Gapin L., Viguier M., Bonnerot C. Type II and III 
receptors for immunoglobulin G (IgG) control the presentation of different T cell 
epitopes from single IgG-complexed antigens. J. Exp. Med. 187: 505-515, 1998. 
Angeli V., Hammad H., Staels B., Capron M., Lambrecht B.N., Trottein F. Peroxisome 
proliferator-activated receptor gamma inhibits the migration of dendritic cells: 
consequences for the immune response. J. Immunol. 170:5295-5301, 2003. 
Appel S., Mirakaj V., Bringmann A., Weck M.M., Grunebach F., Brossart P. PPAR-
gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the 
MAP kinase and NF-kappaB pathways. Blood 106: 3888-3894, 2005. 
Asada K., Sasaki S., Suda T., Chida K., Nakamura H. Antiinflammatory roles of 
peroxisome proliferator-activated receptor gamma in human alveolar macrophages. 
Am. J. Respir. Crit. Care Med. 169: 195-200, 2004. 
Aychek T., Jung S. The axis of tolerance. Science 343: 1439-1440, 2014. 
Bacci S., Alard P., Dai R., Nakamura T., Streilein JW. High and low doses of haptens 
dictate whether dermal or epidermal antigen-presenting cells promote contact 
hypersensitivity. Eur. J. Immunol. 27: 442-448, 1997. 
Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y., Pulendran B., 
Paluka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811, 2000. 
Banchereau J., Palucka K. Dendritic cells as therapeutic vaccines against cancer. Nat. 
Rev. Immunol. 5: 296–306, 2005. 
Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 392: 
245-252, 1998. 
Bani D., Moretti S., Pimpinelli N., Giannotti B. Differentation of monocytes into 
Langherans cells in human epidermis. An ultrastructural study. In: Thivolet J., Schmitt 
D. (Eds.) The Langherans Cell. Colloque INSERM 172, John Libbey Eurotext. 
London, Montrouge. 75-83, 1988. 
  112
Benitez-Ribas D., Tacken P., Punt C.J., de Vries I.J., Figdor C.G. Activation of human 
plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of 
immune complexes and presentation by MHC class II. J. Immunol. 181: 5219-5924, 
2008. 
Berthier-Vergnes O., Gaucherand M., Péguet-Navarro J., Plouet J., Pageaux J.F., 
Schmitt D., Staquet M.J.. Human melanoma cells inhibit the earliest differentiation 
steps of human Langerhans cell precursors but failed to affect the functional 
maturation of epidermal Langerhans cells. Br. J. Cancer 85: 1944-1951, 2001. 
Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with 
H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143: 
1283-1288, 1976. 
Bhawan J., Dayal J., Bhan A.K. Langerhans cells in molluscum contagiosum, verruca 
vulgaris, plantar wart, and condyloma acuminatum. J. am. Acad. Dermatol. 15: 645-
649, 1986. 
Birbeck M.S., Breathnach A.S., Everall J.D. An electron microscopic study of basal 
melanocytes and high level clear cells (Langerhans cell) in vitiligo. J. Invest. 
Dermatol. 37: 51-64, 1961. 
Bjercke S., Elgo J., Braathen L., Thorsby E. Enriched epidermal Langerhans cells are 
potent antigen-presenting cells for T cells. J. Invest. Dermatol. 83: 286-289, 1984. 
Blauvelt A., Katz S.I., Udey M.C. Human Langerhans cells express E-cadherin. J. 
Invest. Dermatol. 104: 293-296, 1995. 
Bobo D., Robinson K.J., Islam J., Thurecht K.J., Corrie S.R . Nanoparticle-based 
medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 
33: 2373-2387, 2016. 
Boczkowski D., Nair S.K., Nam J.H., Lyerly H.K., Gilboa E. Induction of tumor 
immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with 
messenger RNA amplified from tumor cells. Cancer Res. 60: 1028-1034, 2000. 
Bonetti M.I., Bacci S., Santosuosso M., Mazzanti B., Aldinucci A., Ballerini C., Guasti 
D., Calosi L., Bosi A., Romagnoli P. Rosiglitazone promotes the differentiation of 
Langerhans cells and inhibits that of other dendritic cell types from CD133 positive 
hematopoietic precursors. Histol. Histopathol. 29: 323-332, 2014. 
Borkowski T.A., Letterio J.J., Farr A.G., Udey M.C. A role for endogenous 
transforming growth factor β1 in Langerhans cell biology: the skin of transforming 
growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 
184: 2417-2422, 1996. 
Botting R.A., Rana H., Bertram K.M., Rhodes J.W., Baharlou H., Nasr N., Cunningham 
A.L., Harman A.N. Langerhans cells and sexual transmission of HIV and HSV. Rev. 
Med. Virol. 27(2), 2017.  
Braathen L.R., Thorsby E. Studies on human epidermal Langerhans cells. I. Allo-
activating and antigen-presenting capacity. Scand. J. Immunol. 11: 401-408, 1980. 
Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of 
PPARs: tissue distribution of PPAR-alpha, beta and gamma in the adult rat. 
Endocrinology 137: 354-366, 1996. 
Breathnach A.S. The cell of Langerhans. Int. Rev. Citol. 18: 1-28, 1965. 
Brocker T. The role of dendritic cells in T cell selection and survival. J. Leukoc. Biol. 
66: 331-335, 1999. 
Carreno B.M., Collins M. The B7 family of ligands and its receptors: new pathways for 
costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20: 29-53, 
2002. 
  113
Caux C., Massacrier C., Vanbervliet B., Dubois B., Van Kooten C., Durand I., 
Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J. Exp. 
Med. 180: 1263-1272, 1994a. 
Caux C., Vanbervliet B., Massacrier C., Azuma M., Okumura K., Lanier L. L., 
Banchereau J. B70/B7-2 is identical to CD86 and is the major functional ligand for 
CD28 expressed on human dendritic cells. J. Exp. Med. 180: 1841-1847, 1994b. 
Caux C., Vanbervliet B., Massacrier C., Dezutter-Dambuyant C., Desaintvis B., Jacquet 
C., Yoneda K., Imamura S., Schmitt D., Banchereau J. CD34(+) hematopoietic 
progenitors from human cord blood differentiate along two independent dendritic cell 
pathways in response to GM-CSF+TNF alpha. J. Exp. Med. 184: 695-706, 1996. 
Celinski K., Dworzanski T., Korolczuk A., Piasecki R., Slomka M., Madro A., Fornal 
R. Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran 
sodium sulphate-induced colitis in rats. J. Physiol. Pharmacol. 62: 347-356, 2011. 
Cella M., Facchetti F., Lanzavecchia A., Colonna M. Plasmacytoid dendritic cells 
activated by influenza virus and CD40L drive a potent TH1 polarization. Nat. 
Immunol. 1: 305-310, 2000. 
Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting 
function of dendritic cells. Basel Institute for Immunology, Curr. Opin. Immunol. 9: 
10-16, 1997. 
Cerio R., Griffiths C.E.M., Cooper K.D., Nikoloff B.J., Headington J.T. Charaterization 
of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br. J. 
Dermatol. 121: 421, 1989. 
Chakravarthy M.V., Lodhi I.J., Yin L., Malapaka R.R., Xu H.E., Turk J., Semenkovich 
C.F. Identification of a physiologically relevant endogenous ligand for PPARalpha in 
liver. Cell 138: 476-488, 2009. 
Challier J., Bruniquel D., Sewell A.K., Laugel B. Adenosine and cAMP signalling skew 
human dendritic cell differentiation towards a tolerogenic phenotype with defective 
CD8(+) T-cell priming capacity. Immunology 138: 402-410, 2013. 
Chen M., Huang L., Wang J. Deficiency of Bim in dendritic cells contributes to 
overactivation of lymphocytes and autoimmunity. Blood 109: 4360-4367, 2007. 
Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors 
(PPARs): nuclear receptors at the crossroads between lipid metabolism and 
inflammation. Inflamm. Res 49: 497-505, 2000. 
Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., Bawendi M.G., 
Frangioni J.V. Renal clearance of quantum dots. Nat. Biotechnol. 25: 1165-1170, 
2007. 
Chow A.Y., Mellman I. Old lysosomes, new tricks: MHC II dynamics in DCs. Trends 
Immunol. 26: 72-78, 2005. 
Colonna M., Krug A., Cella M. Interferon-producing cells: on the front line in immune 
responses against pathogens. Curr. Opin. Immunol. 14: 373-379, 2002. 
Coosemans A., Baert T., Vergote I. A view on dendritic cell immunotherapy in ovarian 
cancer: how far have we come? Facts Views Vis Obgyn. 7: 73-78, 2015. 
Costa N.L., Gonçalves A.S., Martins A.F., Arantes D.A., Silva T.A., Batista A.C. 
Characterization of dendritic cells in lip and oral cavity squamous cell carcinoma. J. 
Oral. Pathol. Med. 45: 418-424, 2016. 
Cresswell P. Antigen processing and presentation. Immunol. Rev. 207: 5-7, 2005. 
Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., Kelly 
C.J. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in 
vivo. J. Immunol. 169: 6806-6812, 2002. 
  114
Curi D.S., Leite-Ribeiro P.M., Torregrossa V.R., Vieira V.C., Sarmento V.A. Efficacy 
of imidazolquinoline on treatment of condyloma acuminatum of the buccal mucosa. 
Spec. Care Dentist. 37: 51-54, 2017. 
De Vinuesa C.G., Gulbranson-Judge A., Khan M. O'Leary P., Cascalho M., Wabl M., 
Klaus G.B., Owen M.J., MacLennan I.C.M. Dendritic cells associated with 
plasmablast survival. Eur. J. Immunol. 29: 3712-3721, 1999. 
de Witte L., Nabatov A., Pion M., Fluitsma D., de Jong M.A., de Gruijl T., Piguet V., 
van Kooyk Y., Geijtenbeek T.B. Langerin is a natural barrier to HIV-1 transmission 
by Langerhans cells. Nat. Med. 13: 367-371, 2007. 
Denniston A.K., Kottoor S.H., Khan I., Oswal K., Williams G.P., Abbott J., Wallace 
G.R., Salmon M., Rauz S., Murray P.I., Curnow S.J. Endogenous cortisol and TGF-
beta in human aqueous humor contribute to ocular immune privilege by regulating 
dendritic cell function. J. Immunol. 186: 305-311, 2011. 
Dieu M.C., Vanbervliet B., Vicari A., Bridon J.M., Oldham E., Aït-Yahia S., Brière F., 
Zlotnik A., Lebecque S., Caux C. Selective recruitment of immature and mature 
dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. 
Med. 188: 373-386, 1998. 
Dillman R., Selvan S., Schiltz P., Peterson C., Allen K., Depriest C., McClay E., Barth 
N., Sheehy P., de Leon C., Beutel L. Phase I/II trial of melanoma patient-specific 
vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned 
interim analysis. Cancer Biother. Radiopharm. 19: 658-665, 2004. 
Dillman R.O., Selvan S.R., Schiltz P.M., McClay E.F., Barth N.M., DePriest C., de 
Leon C., Mayorga C., Cornforth A.N., Allen K. Phase II trial of dendritic cells loaded 
with antigens from self-renewing, proliferating autologous tumor cells as patient-
specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer 
Biother. Radiopharm. 24: 311-319, 2009. 
Döbel T., Kunze A., Babatz J., Tränkner K., Ludwig A., Schmitz M., Enk A., Schäkel 
K. FcgRIII (CD16) equips immature 6-sulfo LacNAc-expressing dendritic cells 
(slanDCs) with a unique capacity to handle IgG-complexed antigens. Blood 121: 
3609-3618, 2013. 
Dubois B., Massacrier C., Vanbervliet B., Fayette J., Brière F., Banchereau J., Caux C. 
Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. 
J Immunol. 161: 2223-2231, 1998. 
Dudziak D., Kamphorst A.O., Heidkamp G.F, Buchholz V.R., Trumpfheller C., 
Yamazaki S., Cheong C., Liu K., Lee H.W., Park C.G., Steinmanm R.M, Nussenzweig 
M.C. Differential antigen processing by dendritic cell subsets in vivo. Science 315: 
107-111, 2007. 
Dyduch G., Tyrak K.E., Glajcar A., Szpor J., Okoń K. CD207+/langerin positive 
dendritic cells in invasive and in situ cutaneous malignant melanoma. Postepy 
Dermatol Alergol. 34: 233-239, 2017. 
Dzionek A., Fuchs A., Schmidt P., Cremer S., Zysk M., Miltenyi S., Buck DW., 
Schmitz J. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of 
dendritic cells in human peripheral blood. J. Immunol. 165: 6037-6046, 2000. 
Dzionek A., Inagaki Y., Okawa K., Nagafune J., Röck J., Sohma Y., Winkels G., Zysk 
M., Yamaguchi Y., Schmitz J. Plasmacytoid dendritic cells: from specific surface 
markers to specific cellular functions. Hum. Immunol. 63: 1133-1148, 2002. 
Dzionek A., Sohma Y., Nagafune J., Cella M., Colonna M., Facchetti F., Günther G., 
Johnston I., Lanzavecchia A., Nagasaka T., Okada T., Vermi W, Winkels G., 
Yamamoto T., Zysk M., Yamaguchi Y., Schmitz J. BDCA-2, a novel plasmacytoid 
dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent 
inhibitor of interferon alpha/beta induction. J. Exp. Med. 194: 1823-1834, 2001. 
  115
Elder J.T., Reynolds N.J., Cooper K.D., Griffiths C.E., Hardas B.D., Bleicher P.A. CD1 
gene expression in human skin. J. Dermatol. Sci. 6: 206-213, 1993. 
Engering A.J., Cella M., Fluitsma D., Brockhaus M., Hoefsmit E.C., Lanzavecchia A., 
Pieters J. The mannose receptor functions as a high capacity and broad specificity 
antigen receptor in human dendritic cells. Eur. J. Immunol. 27: 2417-2425, 1997. 
Epstein W. Molluscum contagiosum. Semin. Dermatol. 11: 184-189, 1992. 
Erbacher A., Gieseke F., Handgretinger R., Müller I. Dendritic cells: functional aspects 
of glycosylation and lectins. Hum. Immunol. 70: 308-312, 2009. 
Eyerich K., Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 
paradigm. Allergy 68: 974-982, 2013. 
Facchetti F., de Wolf-Peeters C., van den Oord J.J., de Vos R., Desmet V.J. 
Plasmacytoid monocytes (so-called plasmacytoid T-cells) in Kikuchi’s lymphadenitis. 
An immunohistologic study. Am. J. Clin. Pathol. 92: 42-50, 1989. 
Fadeel B., Xue D., Kagan V. Programmed cell clearance: molecular regulation of the 
elimination of apoptotic cell corpses and its role in the resolution of inflammation. 
Biochem. Biophys. Res Commun. 396: 7-10, 2010. 
Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., 
Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., 
Vidal H., Auwerx J. The organization, promoter analysis, and expression of the human 
PPARgamma gene. J Biol. Chem. 272: 18779-18789, 1997. 
Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., 
Belladonna M.L., Fioretti M.C., Alegre M.L., Puccetti P. Modulation of tryptophan 
catabolism by regulatory T cells. Nat. Immunol. 4: 1206-1212, 2003. 
Fanger N.A., Wardwell K., Shen L., Tedder T.F., Guyre P.M. Type I (CD64) and type 
II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. 
J. Immunol. 157: 541-548, 1996. 
Faries M.B., Morton D.L. Therapeutic vaccines for melanoma: current status. BioDrugs. 
19: 247-260, 2005. 
Farthing P.M., Matear P., Cruchley A.T. The activation of Langerhans cells in oral 
lichen planus. J. Oral. Pathol Med. 19: 81-85, 1990. 
Fay J.W., Palucka A.K., Paczesny S., Dhodapkar M., Johnston D.A., Burkeholder S., 
Ueno H., Banchereau J. Long-term outcomes in patients with metastatic melanoma 
vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. 
Cancer Immunol. Immunother. 55: 1209-1218, 2006. 
Fayette J., Durand I., Bridon J.M. Arpin C., Dubois B., Caux C., Liu Y.S., Banchereau 
J., Triere F. Dendritic cells enhance the differentiation of naive B cells into plasma 
cells in vitro. Scand. J. Immunol. 48: 563-570, 1998. 
Fehérvari Z., Sakaguchi S. CD4+ Tregs and immune control. J. Clin. Invest. 114: 1209-
1217, 2004. 
Ficarra G., Cortés S., Rubino I., Romagnoli P. Facial and perioral molluscum 
contagiosum in patients with HIV infection. A report of eight cases. Oral Surg. Oral 
Med. Oral Pathol. 78: 621-626, 1994. 
Fields R.C., Shimizu K., Mule J.J. Murine dendritic cells pulsed with whole tumor 
lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. 
Acad. Sci. USA 95: 9482-9487, 1998. 
Figdor C.G., de Vries I.J., Lesterhuis W.J., Melief C.J. Dendritic cell immunotherapy: 
mapping the way. Nat. Med. 10: 475-480, 2004. 
Fitzergerald-Bocarsly P., Feldman M., Mendelsohn M., Curl S., Lopez C. Human 
mononuclear cells which produce interferon-alpha during NK[HSV-FS] assays are 
HLA-DR positive cells distinct from cytolyltic natural killer effectors. J. Leukoc. Biol. 
43: 323-334, 1988. 
  116
Foerster F., Bamberger D., Schupp J., Weilbächer M., Kaps L., Strobl S., Radi L., 
Diken M., Strand D., Tuettenberg A., Wich P.R., Schuppan D. Dextran-based 
therapeutic nanoparticles for hepatic drug delivery. Nanomedicine 11: 2663-2677, 
2016. 
Fogli S., Montis C., Paccosi S., Silvano A., Michelucci E., Berti D., Bosi A., Parenti A., 
Romagnoli P. Inorganic nanoparticles as potential regulators of immune response in 
dendritic cells. Nanomedicine (Lond). 12: 1647-1660, 2017. 
Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, 
and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and 
delta. Proc. Natl. Acad. Sci. USA 94: 4312-4317, 1997. 
Forrester J.V., Xu H. Good news -bad news: the Yin and Yang of immune privilege in 
the eye. Front. Immunol. 3: 338, 2012. 
Fossum S. Dendritic leukocytes: features of their in vivo physiology. Res. Immunol. 
140: 883-891, 1989. 
Franks H.A., Wang Q., Lax S.J., Collins M.K., Escors D., Patel P.M., Jackson A.M. 
Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) 
myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition 
of p38 enhances IL-12 whilst suppressing IL-10. Int. J. Cancer 134: 575-586, 2013. 
Frens G. Controlled nucleation for the regulation of the particle size in monodisperse 
gold suspensions. Nature 241: 20-22, 1973. 
Frolov A., Dong H., Jiang M., Yang L., Cook E.C., Matnani R., Hammock B.D., 
Crofford L.J. Niemann-Pick type C2 deficiency in human fibroblasts confers robust 
and selective activation of prostaglandin E2 biosynthesis. J. Biol. Chem. 288: 23696-
23703, 2013. 
Fucikova J., Kralikova P., Fialova A., Brtnicky T., Rob L., Bartunkova J., Spísek R. 
Human tumor cells killed by anthracyclines induce a tumor-specific immune response. 
Cancer Res. 71: 4821-4833, 2011. 
Fujita H., Shemer A., Suárez-Fariñas M., Johnson-Huang L.M., Tintle S., Cardinale I., 
Fuentes-Duculan J., Novitskaya I., Carucci J.A., Krueger J.G., Guttman-Yassky E. 
Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit 
parallel ability to activate T-cell subsets. J. Allergy Clin. Immunol. 128: 574-582, 
2011. 
Galluzzi L., Vacchelli E., Bravo-San Pedro J.M., Buqué A., Senovilla L., Baracco E.E., 
Bloy N., Castoldi F., Abastado J.P., Agostinis P., Apte R.N., Aranda F., Ayyoub M., 
Beckhove P., Blay J.Y., Bracci L., Caignard A., Castelli C., Cavallo F., Celis E., 
Cerundolo V., Clayton A., Colombo M.P., Coussens L., Dhodapkar M.V., Eggermont 
A.M., Fearon D.T., Fridman W.H., Fučíková J., Gabrilovich D.I., Galon J., Garg A., 
Ghiringhelli F., Giaccone G., Gilboa E., Gnjatic S., Hoos A., Hosmalin A., Jäger D., 
Kalinski P., Kärre K., Kepp O., Kiessling R., Kirkwood J.M., Klein E., Knuth A., 
Lewis C.E., Liblau R., Lotze M.T., Lugli E., Mach J.P., Mattei F., Mavilio D., Melero 
I., Melief C.J., Mittendorf E.A., Moretta L., Odunsi A., Okada H., Palucka A.K., Peter 
M.E., Pienta K.J., Porgador A., Prendergast G.C., Rabinovich G.A., Restifo N.P., 
Rizvi N., Sautès-Fridman C., Schreiber H., Seliger B., Shiku H., Silva-Santos B., 
Smyth M.J., Speiser D.E., Spisek R., Srivastava P.K., Talmadge J.E., Tartour E., Van 
Der Burg S.H., Van Den Eynde B.J., Vile R., Wagner H., Weber J.S., Whiteside T.L., 
Wolchok J.D., Zitvogel L., Zou W., Kroemer G. Classification of current anticancer 
immunotherapies. Oncotarget 5: 12472-12508, 2014. 
García-Vallejo J.J., Ambrosini M., Overbeek A., van Riel W.E., Bloem K., Unger 
W.W., Chiodo F., Bolscher J.G., Nazmi K., Kalay H., van Kooyk Y. Multivalent 
glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells. Mol. 
Immunol. 53: 387-397, 2013. 
  117
Geijtenbeek T.B., Gringhuis S.I. Signalling through C-type lectin receptors: shaping 
immune responses. Nat. Rev. Immunol. 9: 465-479, 2009. 
Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., 
Middel J., Cornelissen I.L., Nottet H.S., Kewalramani V.N., Littman D.R., Figdor 
C.G., van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that 
enhances trans-infection of T cells. Cell 100: 587-597, 2000a. 
Geijtenbeek T.B., Torensma R., van Vliet S.J., van Duijnhoven G.C., Adema G.J., van 
Kooyk Y., Figdor C.G. Identification of DC-SIGN, a novel dendritic cell-specific 
ICAM-3 receptor that supports primary immune responses. Cell 100: 575-585, 2000b. 
Geissmann F., Prost C., Monnet J.P., Dy M., Brousse N., Hermine O. Transforming 
Growth Factor β1, in the Presence of Granulocyte/Macrophage Colony-stimulating 
Factor and Interleukin 4, Induces Differentiation of Human Peripheral Blood 
Monocytes into Dendritic Langerhans Cells. J. Exp. Med. 187: 961-966, 1998. 
Geissmann F., Revy P., Brousse N., Lepelletier Y., Folli C., Durandy A., Chambon P., 
Dy M. Retinoids regulate survival and antigen presentation by immature dendritic 
cells. J. Exp. Med. 198: 623-634, 2003. 
Gerlini G., Di Gennaro P., Mariotti G., Urso C., Chiarugi A., Caporale R., Pimpinelli 
N., Borgognoni L. Human Langerhans cells are immature in melanoma sentinel lymph 
nodes Blood 119: 4807-4808, 2012a. 
Gerlini G., Di Gennaro P., Borgognoni L. Enhancing anti-melanoma immunity by 
electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 1: 1655-
1657, 2012b. 
Giomi B., Pagnini F., Cappuccini A., Bianchi B., Tiradritti L., Zuccati G. 
Immunological activity of photodynamic therapy for genital warts. Br. J. Dermatol. 
164: 448-451, 2011. 
Gold M.H., Moiin A. Treatment of verrucae vulgaris and molluscum contagiosum with 
photodynamic therapy. Dermatol. Clin. 25: 75-80, 2007. 
Goordyal P., Isaacson P.G. Immunocytochemical characterization of monocyte colonies 
of human bone marrow: A clue to the origin of Langerhans cells and interdigitating 
reticulum cells. J. Pathol. 146: 189-195, 1985. 
Gorouhi F., Davari P., Fazel N. Cutaneous and mucosal lichen planus: a comprehensive 
review of clinical subtypes, risk factors, diagnosis, and prognosis. Scientific World 
Journal. 2014:742826, 2014. 
Gosset P., Charbonnier A.S., Delerive P., Fontaine J., Staels B., Pestel J., Tonnel A.B., 
Trottein F. Peroxisome proliferator-activated receptor gamma activators affect the 
maturation of human monocyte-derived dendritic cells. Eur. J. Immunol. 31: 2857-
2865, 2001. 
Green I., Stingl G., Shevach E. M., Katz S. I. Antigen presentation and allogeneic 
stimulation by Langerhans cells. J. Invest. Dermatol. 75: 44-45, 1980. 
Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Kwan K., Hsieh L., 
Greene G., Nimer S.D. Isolation of the human peroxisome proliferator activated 
receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. 
Gene Expr. 4: 281-299, 1995. 
Greter M., Helft J., Chow A., Hashimoto D., Mortha A., Agudo-Cantero J., Bogunovic 
M., Gautier E.L., Miller J., Leboeuf M., Lu G., Aloman C., Brown B.D., Pollard J.W., 
Xiong H., Randolph G.J., Chipuk J.E., Frenette P.S., Merad M. GM-CSF controls 
nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation 
of inflammatory dendritic cells. Immunity 36: 1031-1046, 2012. 
Haemmerle G., Moustafa T., Woelkart G., Büttner S., Schmidt A., van de Weijer T., 
Hesselink M., Jaeger D., Kienesberger P.C., Zierler K., Schreiber R., Eichmann T., 
Kolb D., Kotzbeck P., Schweiger M., Kumari M., Eder S., Schoiswohl G., Wongsiriroj 
  118
N., Pollak N.M., Radner F.P., Preiss-Landl K., Kolbe T., Rülicke T., Pieske B., 
Trauner M., Lass A., Zimmermann R., Hoefler G., Cinti S., Kershaw E.E., Schrauwen 
P., Madeo F., Mayer B., Zechner R. ATGL-mediated fat catabolism regulates cardiac 
mitochondrial function via PPAR-α and PGC-1. Nat. Med. 17: 1076-1085, 2011. 
Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey 
P., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., 
Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., 
Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. Safety 
and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 
369: 134–144, 2013. 
Hammad H., de Heer H.J., Soullié T., Angeli V., Trottein F., Hoogsteden H.C., 
Lambrecht B.N. Activation of peroxisome proliferator-activated receptor-gamma in 
dendritic cells inhibits the development of eosinophilic airway inflammation in a 
mouse model of asthma. Am. J. Pathol. 164:263-271, 2004. 
Han H., Liang X., Ekberg M., Kritikou J.S., Brunnström Å., Pelcman B., Matl M., Miao 
X., Andersson M., Yuan X., Schain F., Parvin S., Melin E., Sjöberg J., Xu D., 
Westerberg L.S., Björkholm M., Claesson H.E. Human 15-lipoxygenase-1 is a 
regulator of dendritic-cell spreading and podosome formation. FASEB J. 31: 491-504, 
2017. 
Hanau D., Fabre M., Schmitt D.A., Garaud J.-C., Pauly G., Cazenave J.-P. Appearance 
of Birbeck granule-like structures in anti-T6 antibody-treated human epidermal 
Langerhans cells. J. Invest. Dermatol. 90: 298-304, 1988.  
Haroche J., Cohen-Aubart F., Rollins B.J., Donadieu J., Charlotte F., Idbaih A., Vaglio 
A., Abdel-Wahab O., Emile J.F., Amoura Z. Histiocytoses: emerging neoplasia behind 
inflammation. Lancet Oncol. 18: e113-e125, 2017.  
Harrist T.J., Bhan A.K., Murphy G.F., Sato S., Berman R.S., Gellis S.E., Freedman S., 
Mihm M.C. Jr. Histiocytosis-X: in situ characterization of cutaneous infiltrates with 
monoclonal antibodies. Am. J. Clin. Pathol. 79: 294-300, 1983. 
Hart D.N. Dendritic cells: unique leukocytes populations which control the primary 
immune response. Blood 90: 3245-3287, 1997. 
Haskó G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects 
for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7: 759-770, 2008. 
Hazenberg M.D., Spits H. Human innate lymphoid cells. Blood 124: 700-709, 2014. 
Headington J.T. The dermal dendrocytes. Adv. Dermatol. 1: 159-171, 1986. 
Hengartner H., Odermatt B., Schneider R., Schreyer M., Wälle G., MacDonald H.R., 
Zinkernagel R.M. Deletion of self-reactive T cells before entry into the thymus 
medulla. Nature 336: 388-390, 1988. 
Hespel C., Moser M. Role of inflammatory dendritic cells in innate and adaptive 
immunity. Eur. J. Immunol. 42: 2535-2543, 2012. 
Hinz B., Brune K., Pahl A. 15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the 
expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-
independent mechanism. Biochem. Biophys. Res Commun. 302:415-420, 2003. 
Hirakata M., Tozawa R., Imura Y., Sugiyama Y. Comparison of the effects of 
pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem. Biophys. 
Res Commun. 323: 782-788, 2004. 
Hirayama M., Nishimura Y. The present status and future prospects of peptide-based 
cancer vaccines. Int. Immunol. 28: 319-328, 2016. 
Hoefsmit E.C., Balfour B.M., Kamperdijk E.W., Cvetanov J. Cells containing Birbeck 
granules in the lymph and the lymph node. Adv. Exp. Med. Biol. 114: 389-394, 1979. 
Hoefsmit E.C., Dujvestijn A.M., Kamperdijk E.W. Relation between Langerhans cells, 
veiled cells, and interdigitating cells. Immunobiology 161: 255-265, 1982. 
  119
Hsu P., Nanan R. Foetal immune programming: hormones, cytokines, microbes and 
regulatory T cells. J. Reprod. Immunol. 104-105:2-7, 2014. 
Hu F.Q., Hong Y., Yuan H. Preparation and characterization of solid lipid nanoparticles 
containing peptide. Int. J. Pharm. 273: 29-35, 2004. 
Hubert P., Bousarghin L., Greimers R., Franzen-Detrooz E., Boniver J., Delvenne P. 
Production of large numbers of Langerhans' cells with intraepithelial migration ability 
in vitro. Exp. Dermatol. 14: 469-477, 2005. 
Hunger R.E., Sieling P.A., Ochoa M.T., Sugaya M., Burdick A.E., Rea T.H., Brennan 
P.J., Belisle J.T., Blauvelt A., Porcelli S.A., Modlin R.L. Langerhans cells utilize 
CD1a and langerin to efficiently present nonpeptide antigens to T cells. J. Clin. Invest. 
113: 701-708, 2004. 
Idoyaga J., Cheong C., Suda K., Suda N., Kim J.Y., Lee H, Park C.G. and Steiman 
R.M. Langerin/CD207 receptor on dendritic cells mediates efficient antigen 
presentation on MHC I and II products in vivo. J. Immunol. 180: 3647-3650, 2008. 
Iitaka D., Moodley S., Shimizu H., Bai X.H., Liu M. PKCδ-iPLA2-PGE2-PPARγ 
signaling cascade mediates TNF-α induced Claudin 1 expression in human lung 
carcinoma cells. Cell. Signal. 27: 568-577, 2015. 
Inaba K., Inaba M., Naito M., Steinman R.M. Dendritic cell progenitors phagocytose 
particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to 
mycobacterial antigens in vivo. J. Exp. Med. 178: 479-88, 1993. 
Inaba K., Steinman R.M. Protein-specific helper T-lymphocyte formation initiated by 
dendritic cells. Science 229: 475-479, 1985. 
Irvine A.S., Trinder P.K., Laughton D.L., Ketteringham H., McDermott R.H., Reid 
S.C., Haines A.M., Amir A., Husain R., Doshi R., Young L.S., Mountain A. Efficient 
nonviral transfection of dendritic cells and their use for in vivo immunization. Nat. 
Biotechnol. 18: 1273-1278, 2000. 
Issemann I., Green S. Activation of a member of the steroid hormone receptor 
superfamily by peroxisome proliferators. Nature 347: 645-650, 1990. 
Ito T., Inaba M., Inaba K., Toki J., Sogo S., Iguchi T., Adachi Y., Yamaguchi K., 
Amakawa R., Valladeau J., Saeland S., Fukuhara S., Ikehara S. A CD1a+/CD11c+ 
subset of human blood dendritic cells is a direct precursor of Langerhans cells. J. 
Immunol. 163: 1409-1419, 1999. 
Jackson M., Benton E.C., Hunter J.A.A., Norval M. Local immune responses in 
cutaneous warts: An immunocytochemical study of Langerhans' cells, T cells and 
adhesion molecules. Eur. J. Dermatol. 4: 399-404, 1994. 
Jakob T., Brown M.J., Udey M.C. Characterization of E-cadherin-containing junctions 
involving skin-derived dendritic cells. J. Invest. Dermatol. 112: 102-108, 1999. 
Jenkins, M.K., Schwartz R.H. Antigen presentation by chemically modified splenocytes 
induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 
165: 302-319, 1987. 
Jensen T.O., Schmidt H., Møller H.J., Donskov F., Høyer M., Sjoegren P., Christensen 
I.J., Steiniche T. Intratumoral neutrophils and plasmacytoid dendritic cells indicate 
poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II 
melanoma. Cancer 118: 2476-2485, 2012. 
Johnson D.J., Ohashi P.S. Molecular programming of steady-state dendritic cells: 
impact on autoimmunity and tumor immune surveillance. Ann. N. Y. Acad. Sci. 
1284:46-51, 2013. 
Jung K., Tanaka A., Fujita H., Matsuda A., Oida K., Karasawa K., Okamoto N., Ohmori 
K., Jee Y., Shin T., Matsuda H. Peroxisome proliferator-activated receptor γ-mediated 
suppression of dendritic cell function prevents the onset of atopic dermatitis in 
NC/Tnd mice. J. Allergy Clin. Immunol. 127:420-429, 2011. 
  120
Kaiserling E., Lennert K. Die interdigitierende Reticulumzellen im menschlichen 
Lymphknoten. Eine spezifische Zelle der thymusabhängigen Region. Virchows Arch. 
B 16: 51-61, 1974. 
Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern 
C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F.; 
IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant 
prostate cancer. N. Engl. J. Med. 363: 411-22, 2010. 
Kaplan D.H., Igyártó B.Z., Gaspari A.A. Early immune events in the induction of 
allergic contact dermatitis. Nat. Rev. Immunol. 12, 114–124, 2012. 
Katz S. I., Tamaki K., Sachs D.H. Epidermal Langerhans cells are derived from cells 
originating in bone marrow. Nature 282: 324-326, 1979. 
Kelly R.H., Balfour B.M., Armstrong J.A., Griffiths S. Functional anatomy of lymph 
nodes. II. Peripheral lymph-bone mononuclear cells. Anat. Rec. 190: 5-22, 1978. 
Klechevsky E., Banchereau J. Human dendritic cells subset as targets and vectors for 
therapy. Ann. N. Y. Acad. Sci. 1284: 24-30, 2013. 
Klechevsky E., Liu M., Morita R., Banchereau R., Thompson-Snipes L., Palucka A.K., 
Ueno H., Banchereau J. Understanding human myeloid dendritic cell subsets for the 
rational design of novel vaccines. Hum. Immunol. 70: 281-88, 2009. 
Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. A 
prostaglandin J2 metabolite binds peroxisome proliferatoractivated receptor γ and 
promotes adipocyte differentiation. Cell 83: 813-819, 1995. 
Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., 
Devchand P., Wahli W., Willson T.M., Lenhard J.M., Lehmann J.M. Fatty acids and 
eicosanoids regulate gene expression through direct interactions with peroxisome 
proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U S A 94: 
4318-4323, 1997. 
Koszik F., Strunk D., Simonitsch I., Picker L.J., Stingl G., Payer E. Expression of 
monoclonal antibody HECA-452-defined E-selectin ligands on Langerhans cells in 
normal and diseased skin. J. Invest. Dermatol. 102: 773-780, 1994. 
Kozak K.R., Gupta R.A., Moody J.S., Ji C., Boeglin W.E., DuBois R.N., Brash A.R., 
Marnett L.J. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a 
peroxisome proliferator-activated receptor alpha agonist. J. Biol. Chem. 277: 23278-
2386, 2002. 
Kreiter S., Selmi A., Diken M., Koslowski M., Britten C.M., Huber C., Türeci O., Sahin 
U. Intranodal vaccination with naked antigen-encoding RNA elicits potent 
prophylactic and therapeutic antitumoral immunity. Cancer Res. 70: 9031-9040, 2010. 
Kumar C., Kohli S., Bapsy P.P., Vaid A.K., Jain M., Attili V.S., Sharan B. Immune 
modulation by dendritic-cell-based cancer vaccines. J. Biosci. 42: 161-173, 2017. 
Kushwah R., Hu J. Complexity of dendritic cell subsets and their function in the host 
immune system. Immunology 133: 409-419, 2011. 
La Rocca C., Carbone F., Longobardi S., Matarese G. The immunology of pregnancy: 
regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett. 
162: 41-8, 2014. 
Labidi-Galy S.I., Treilleux I., Goddard-Leon S., Combes J.D., Blay J.Y., Ray-Coquard 
I., Caux C., Bendriss-Vermare N. Plasmacytoid dendritic cells infiltrating ovarian 
cancer are associated with poor prognosis. Oncoimmunology 1:380-382, 2012. 
Laman J.D., Leenen P.J., Annels N.E., Hogendoorn P.C., Egeler R.M. Langerhans-cell 
histiocytosis 'insight into DC biology'. Trends Immunol. 24: 190-196, 2003. 
Lambe K.G., Tugwood J.D. A human peroxisome-proliferator-activated receptor-γ is 
activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. 
Biochem. 239: 1-7, 1996. 
  121
Larregina A.T., Morelli A.E., Spencer L.A., Logar A.J., Watkins S.C., Thomson A.W., 
Falo L.D.Jr. Dermal-resident CD14+ cells differentiate into Langerhans cells. Nature 
Immunology 2: 1151-1158, 2001. 
Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 123:.993-999, 2005. 
Lemaitre B., Nicolas E., Michaut L., Reichhart J. M., Hoffmann J.A. The dorsoventral 
regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in 
Drosophila adults. Cell 86: 973-983, 1996. 
Lesterhuis W.J., Haanen J.B., Punt C.J. Cancer immunotherapy--revisited. Nat. Rev. 
Drug Discov. 10: 591-600, 2011. 
Leung A.K., Barankin B., Hon K.L. Molluscum contagiosum: an update. Recent Pat 
Inflamm. Allergy Drug Discov. 11: 22-31, 2017. 
Lewis K.L., Reizis B. Dendritic cells: arbiters of immunity and immunological 
tolerance. Cold Spring Harb. Perspect Biol. 4: a007401, 2012. 
Ley K. The role of selectins in inflammation and disease. Trends Mol. Med. 9: 263-268, 
2003. 
Li P., Liu F., Sun L., Zhao Z., Ding X., Shang D., Xu Z., Sun C. Chemokine receptor 7 
promotes cell migration and adhesion in metastatic squamous cell carcinoma of the 
head and neck by activating integrin αvβ3. Int. J. Mol. Med. 27: 679-87, 2011. 
Liang B., Workman C., Lee J., Chew C., Dale B.M., Colonna L., Flores M., Li N., 
Schweighoffer E., Greenberg S., Tybulewicz V., Vignali D., Clynes R. Regulatory T 
cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC 
class II. J. Immunol. 180: 5916-5926, 2008. 
Lin A.Y., Lunsford J., Bear A.S., Young J.K., Eckels P., Luo L., Foster A.E., Drezek 
R.A. High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine 
presentation by dendritic cells in vitro. Nanoscale Res Lett. 8: 72, 2013. 
Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic 
cell precursors. Annu. Rev. Immunol. 23: 275-306, 2005. 
Lowes M.A., Bowcock A.M., Krueger, J.G. Pathogenesis and therapy of psoriasis. 
Nature 445: 866–873, 2007. 
Luconi M., Cantini G., Serio M. Peroxisome proliferator-activated receptor gamma 
(PPARgamma): Is the genomic activity the only answer? Steroids 75: 585-594, 2010. 
Lúdvíksson B.R., Ehrhardt R.O., Strober W. Role of IL-12 in intrathymic negative 
selection. J. Immunol. 163: 4349-4359, 1999. 
Luo Y., Liang C., Xu C., Jia Q., Huang D., Chen L., Wang K., Wu Z., Ge J. Ciglitazone 
inhibits oxidized-low density lipoprotein induced immune maturation of dendritic 
cells. J. Cardiovasc. Pharmacol. 44: 381-385, 2004. 
Ma Y., Shurin G.V., Peiyuan Z., Shurin M.R. Dendritic cells in the cancer 
microenvironment. J. Cancer 4: 36-44, 2013.  
Mahnke K., Guo M., Lee S., Sepulveda H., Swain S.L., Nussenzweig M., Steinman 
R.M. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance 
antigen presentation via major histocompatibility complex class II-positive lysosomal 
compartments. J. Cell Biol. 151: 673-84, 2000. 
Majai G., Gogolák P., Ambrus C., Vereb G., Hodrea J., Fésüs L., Rajnavölgyi E. 
PPARγ modulated inflammatory response of human dendritic cell subsets to engulfed 
apoptotic neutrophils. J. Leukoc. Biol. 88: 981-991, 2010. 
Majai G., Sarang Z., Csomós K., Zahuczky G., Fésüs L. PPARgamma-dependent 
regulation of human macrophages in phagocytosis of apoptotic cells. Eur. J. Immunol. 
37: 1343-1354, 2007. 
Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., 
Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor 
superfamily: the second decade. Cell 83: 835-839, 1995. 
  122
Marx N., Bourcier T., Sukhova G.K., Libby P., Plutzky J. PPARgamma activation in 
human endothelial cells increases plasminogen activator inhibitor type-1 expression: 
PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. 
Biol. 19: 546-551, 1999. 
Mashima R., Okuyama T. The role of lipoxygenases in pathophysiology; new insights 
and future perspectives. Redox Biol. 6: 297-310, 2015. 
Masson P. Pigment cells in man. Ann. N. Y. Acad. Sci. 4: 15-51, 1948. 
Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo L.D., Melief 
C.J., Ildstad S.T., Kast W.M., Deleo A.B. et al. Bone marrow-derived dendritic cells 
pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour 
immunity. Nat. Med. 1: 1297-302, 1995. 
McDermott R., Ziylan U., Spehner D., Bausinger H., Lipsker D., Mommaas M., 
Cazenave J.P., Raposo G., Goud B., de la Salle H., Salamero J., Hanau D. Birbeck 
granules are subdomains of endosomal recycling compartment in human epidermal 
Langerhans cells, which form where langerin accumulates. Mol. Biol. Cell. 13: 317-
335, 2002. 
McDonald R.J., McDonald J.S., Kallmes D.F., Jentoft M.E., Paolini M.A., Murray D.L., 
Williamson E.E., Eckel L.J. Gadolinium deposition in human brain tissues after 
contrast-enhanced MR Imaging in adult patients without intracranial abnormalities. 
Radiology 285: 546-554, 2017. 
McKenna K., Beignon S., Bhardwaj N. Plasmacytoid dendritic cells: linking innate and 
adaptive immunity. J. Virolo. 79: 17-27, 2005. 
Medewar P.B. Imminological tolerance. Nature 189: 14-17, 1961. 
Medzhitov R., Preston-Hurlburt P., Janeway C.A. Jr. A human homologue of the 
Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 
1997. 
Merad M., Ginhoux F., Collin M. Origin, homeostasis and function of Langerhans cells 
and other langerin-expressing dendritic cells. Nat Rev Immunol. 8: 935-947, 2008. 
Merad M., Manz M.G., Karsunky H., Wagers A., Peters W., Charo I., Weissman I.L, 
Cyster J.G., Engleman E.G. Langerhans cells renew in the skin throughout life under 
steady-state conditions. Nat. Immunol. 3 : 1135-1141, 2002. 
Metlay J.P., Pure E., Steinmann R.M. Control of the immune response at the level of 
antigen presenting cells. A comparison of the function of dendritic cells and 
lymphocytes. B. Adv. Immunol. 47: 45-116, 1989. 
Michalik L., Desvergne B., Wahli W. Peroxisome proliferator-activated receptors 
beta/delta: Emerging roles for a previously neglected third family member. Curr. Opin. 
Lipidol. 14: 129-135, 2003. 
Miltenyi S., Müller W., Weichel W., Radbruch A. High gradient magnetic cell 
separation with MACS. Cytometry 11: 231-238, 1990. 
Misra P., Owuor E.D., Li W., Yu S., Qi C., Meyer K., Zhu Y.J., Rao M.S., Kong A.N., 
Reddy J.K. Phosphorylation of transcriptional coactivator peroxisome proliferator-
activated receptor (PPAR)-binding protein (PBP). Stimulation of transcriptional 
regulation by mitogen-activated protein kinase. J. Biol. Chem. 277: 48745-48754, 
2002. 
Mizumoto N., Takashima A. CD1a and langerin: acting as more than Langerhans cell 
markers. J. Clin. Invest. 113: 658-660, 2004. 
Mommaas A.M., Mulder A.A., Jordens R., Out C., Tan M.C., Cresswell P., Kluin P.M., 
Koning F. Human epidermal Langerhans cells lack functional mannose receptors and a 
fully developed endosomal/lysosomal compartment for loading of HLA class II 
molecules. Eur. J. Immunol. 29: 571-580, 1999. 
  123
Montagna W., Parrakkal P.F. The structure and function of skin. 3dr. edn. Academic 
Press, New York: 86-88, 1974. 
Montoya C.J., Jie H.B., Al-Harthi L., Mulder C., Patiño P.J., Rugeles M.T., Krieg A.M., 
Landay A.L., Wilson S.B. Activation of plasmacytoid dendritic cells with TLR9 
agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. 
J. Immunol. 177: 1028-1039, 2006. 
Moore G.Y., Pidgeon G.P. Cross-talk between cancer cells and the tumour 
microenvironment: the role of the 5-lipoxygenase pathway. Int. J. Mol. Sci. 18 pii: 
E236 [27 pages], 2017.  
Morelli A.E., Belardi G., Di Paola G., Paredes A., Fainboim L. Cellular subsets and 
epithelial ICAM-1 and HLA-Dr expression in human papillomavirus infection of the 
vulva. Acta dermato-venereol. 74: 45-50, 1994. 
Moretta L., Ferlazzo G., Mingari M.C., Melioli G., Moretta A. Human natural killer cell 
function and their interactions with dendritic cells. Vaccine 2: S38-42, 2003. 
Morton D.L., Foshag L.J., Hoon D.S., Nizze J.A., Famatiga E., Wanek L.A., Chang C., 
Davtyan D.G., Gupta R.K., Elashoff R. et al. Prolongation of survival in metastatic 
melanoma after active specific immunotherapy with a new polyvalent melanoma 
vaccine. Ann. Surg. 216: 463-482, 1992. 
Morton D.L., Foshag L.J., Nizze J.A., Gupta R.K., Famatiga E., Hoon D.S., Irie R.F. 
Active specific immunotherapy in malignant melanoma. Semin. Surg. Oncol. 5: 420-
425, 1989. 
Muszbek L., Bereczky Z., Bagoly Z., Komáromi I., Katona É. Factor XIII: a 
coagulation factor with multiple plasmatic and cellular functions. Physiol. Rev. 91: 
931-972, 2011. 
Nakahigashi K., Doi H., Otsuka A., Hirabayashi T., Murakami M., Urade Y., Zouboulis 
C.C., Tanizaki H., Egawa G., Miyachi Y., Kabashima K. PGD2 induces eotaxin-3 via 
PPARγ from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J. 
Allergy Clin. Immunol. 129: 536-543, 2012. 
Nencioni A., Grunebach F., Zobywlaski A., Denzlinger C., Brugger W., Brossart P. 
Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated 
receptor gamma. J. Immunol. 169:.1228-1235, 2002. 
Nestle F.O., Zheng X.G., Thompson C.B., Turka L.A., Nickoloff B.J. Characterization 
of dermal dendritic cells obtained from normal human skin reveals phenotypic and 
functionally distinctive subsets. J. Immunol. 151: 6535-6545, 1993. 
Nussenzweig M.C., Steinman R.M., Witmer M.D., Gutchinov B. A monoclonal 
antibody specific for mouse dendritic cells. Proc. Natl. Acad. Sci. U S A. 79 : 161-165, 
1982. 
Ochoa M.T., Loncaric A., Krutzik S.R., Becker T.C., Modlin R.L. "Dermal dendritic 
cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ 
macrophages. J. Invest. Dermatol. 128: 2225-2231, 2008. 
Ott P.A., Hu Z., Keskin D.B., Shukla S.A., Sun J., Bozym D.J., Zhang W., Luoma A., 
Giobbie-Hurder A., Peter L., Chen C., Olive O., Carter T.A., Li S., Lieb D.J., 
Eisenhaure T., Gjini E., Stevens J., Lane W.J., Javeri I., Nellaiappan K., Salazar A.M., 
Daley H., Seaman M., Buchbinder E.I., Yoon C.H., Harden M., Lennon N., Gabriel S., 
Rodig S.J., Barouch D.H., Aster J.C., Getz G., Wucherpfennig K., Neuberg D., Ritz J., 
Lander E.S., Fritsch E.F., Hacohen N., Wu C.J. An immunogenic personal neoantigen 
vaccine for patients with melanoma. Nature 547: 217-221, 2017. 
Paccosi S., Musilli C., Caporale R., Gelli A.M., Guasti D., Clemente A.M., Torcia 
M.G., Filippelli A., Romagnoli P., Parenti A. Stimulatory interactions between human 
coronary smooth muscle cells and dendritic cells. PLoS One 9: e99652, 2014. 
  124
Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 
12: 265-277, 2012. 
Park Y.M., Lee S.J., Kim Y.S., Lee M.H., Cha G.S., Jung I.D., Kang T.H., Han H.D. 
Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw. 13: 
177-183, 2013. 
Pascual G., Glass C.K. Nuclear receptors versus inflammation: mechanisms of 
transrepression. Trends Endocrinol. Metab. 17: 321-327, 2006. 
Peiser M., Grützkau A., Wanner R., Kolde G. CD1a and CD1c cell sorting yields a 
homogeneous population of immature human Langerhans cells. J. Immunol. Methods 
279: 41-53, 2003. 
Perera G.K., Di Meglio P., Nestle, F.O. Psoriasis. Annu. Rev. Pathol. 7: 385–422, 2012. 
Perreault C., Pelletier M., Landry D., Gyger M. Study of Langerhans cells after 
allogeneic bone marrow transplantation. Blood 63: 807-811, 1984. 
Pimpinelli N., Santucci M., Romagnoli P., Giannotti B. Dendritic cells in T- and B-cell 
proliferation in the skin. Dermatol. Clin. 12: 255-270, 1994. 
Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos 
E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler 
B. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 
gene. Science 282: 2085-2088, 1998. 
Porcelli S.A., Modlin R.L. The CD1 system: antigen-presenting molecules for T cell 
recognition of lipids and glycolipids. Annu. Rev. Immunol. 17 :297-329, 1999. 
Powell W.S., Rokach J. Biosynthesis, biological effects, and receptors of 
hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) 
derived from arachidonic acid. Biochim. Biophys. Acta 1851: 340-355, 2015. 
Prasad S., Cody V., Saucier-Sawyer J.K., Saltzman W.M., Sasaki C.T., Edelson R.L., 
Birchall M.A., Hanlon D.J. Polymer nanoparticles containing tumor lysates as antigen 
delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 7: 
1-10, 2011. 
Probst H.C., Muth S., Schild H. Regulation of the tolerogenic function of steady-state 
DCs. Eur. J. Immunol. 44: 927-93, 2014. 
Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes 
through lymphatic vessels. Nat. Rev. Immunol. 5: 617-28, 2005. 
Rathmell J.C., Thompson C.B. Pathways of apoptosis in lymphocyte development, 
homeostasis, and disease. Cell. 109 Suppl.: S97-107, 2002. 
Rega A., Terlizzi M., Luciano A., Forte G., Crother T.R., Arra C., Arditi M., Pinto A., 
Sorrentino R. Plasmacytoid dendritic cells play a key role in tumor progression in 
lipopolysaccharide-stimulated lung tumor-bearing mice. J. Immunol. 190: 2391-2402, 
2013. 
Reits E.A., Vos J.C., Grommé M., Neefjes J. The major substrates for TAP in vivo are 
derived from newly synthesized proteins. Nature 404: 774-778, 2000. 
Reizis B., Bunin A., Ghosh H.S., Lewis K.L., Sisirak V. Plasmacytoid dendritic cells: 
recent progress and open questions. Annu. Rev. Immunol. 29: 163-183, 2011. 
Reka A.K., Goswami M.T., Krishnapuram R., Standiford T.J., Keshamouni V.G. 
Molecular cross-regulation between PPAR-γ and other signaling pathways: 
implications for lung cancer therapy. Lung Cancer 72: 154-159, 2011. 
Rescigno M., Granucci F., Citterio S., Foti M., Ricciardi-Castagnoli P. Coordinated 
events during bacteria-induced DC maturation. Immunol. Today 20: 200-203, 1999. 
Ribuffo A., Carlesimo O.A., Calvieri S., Chimenti S., Nini G., Panasiti G., Clerico R., 
Ribuffo M., Bottoni U., Cantoresi F., Zampetti M. (1983) I linfomi non propri della 
cute (non Hodgkin). Lombarda, Roma. 
  125
Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome 
proliferatoractivated receptor-gamma is a negative regulator of macrophage activation. 
Nature 391: 79, 1998. 
Robertson S.A., Guerin L.R., Moldenhauer L.M., Hayball J.D. Activating T regulatory 
cells for tolerance in early pregnancy - the contribution of seminal fluid. J. Reprod. 
Immunol. 83: 109-116, 2009. 
Rodríguez E.M., Caorsi I. A second look at the ultrastructure of the Langerhans cell of 
the human epidermis. J. Ultrastruc.t Res. 65: 279-295, 1978. 
Romagnoli P. Dendritic cells in the skin and mucosa: what's new. J. Eur. Acad. 
Dermatol. Venereol. 15: 110-111, 2001. 
Romagnoli P., Moretti S., Fattorossi A., Giannotti B. Dendritic cells in the dermal 
infiltrate of Sézary syndrome. Histopathology 10: 25-36, 1986. 
Romagnoli P., Pimpinelli N., Lotti T., Dendritic cells in the skin and oral mucosa. Ital. 
Gen. Rev. of Dermatol. Vol.28, n 2: 49-79, 1991. 
Romagnoli P., Pimpinelli N., Mori M., Reichart P.A., Eversole L.R., Ficarra G. 
Immunocompetent cells in oral candidiasis of HIV-infected patients: an 
immunohistochemical and electron microscopical study. Oral Dis. 3: 99-105, 1997. 
Romani N., Clausen B.E., Stoitzner P. Langerhans cells and more: langerin-expressing 
dendritic cell subsets in the skin. Immunol. Rev. 234: 120-141, 2010. 
Romani N., Holzmann S., Tripp C.H., Koch F., Stoitzner P. Langerhans cells - dendritic 
cells of the epidermis. APMIS 111: 725-740, 2003. 
Romani N., Ratzinger G., Pfaller K., Salvenmoser W., Stössel H., Koch F., Stoitzner P. 
Migration of dendritic cells into lymphatics-the Langerhans cell example: routes, 
regulation, and relevance. Int. Rev. Cytol. 207: 237-270, 2001. 
Rowden G., Lewis M.G., Sullivan A.K. Ia antigen expression on human epidermal 
Langerhans cells. Nature 268: 247-248, 1977. 
Sadauskas E., Wallin H., Stoltenberg M., Vogel U., Doering P., Larsen A., Danscher G. 
Kupffer cells are central in the removal of nanoparticles from the organism. Part. Fibre 
Toxicol. 4:10, 2007. 
Sahin U., Derhovanessian E., Miller M., Kloke B.P., Simon P., Löwer M., Bukur V., 
Tadmor A.D., Luxemburger U., Schrörs B., Omokoko T., Vormehr M., Albrecht C., 
Paruzynski A., Kuhn A.N., Buck J., Heesch S., Schreeb K.H., Müller F., Ortseifer I., 
Vogler I., Godehardt E., Attig S., Rae R., Breitkreuz A., Tolliver C., Suchan M., 
Martic G., Hohberger A., Sorn P., Diekmann J., Ciesla J., Waksmann O., Brück A.K., 
Witt M., Zillgen M., Rothermel A., Kasemann B., Langer D., Bolte S., Diken M., 
Kreiter S., Nemecek R., Gebhardt C., Grabbe S., Höller C., Utikal J., Huber C., Loquai 
C., Türeci Ö. Personalized RNA mutanome vaccines mobilize poly-specific 
therapeutic immunity against cancer. Nature 547: 222-226, 2017. 
Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured 
human dendritic cells is maintained by granulocyte/macrophage colony-stimulating 
factor plus interleukin 4 and downregulated by tumor necrosis factor. J. Exp. Med. 
179: 1109-1118, 1994. 
Satpathy A.T., KC W., Albring J.C., Edelson B.T., Kretzer N.M., Bhattacharya D., 
Murphy T.L., Murphy K.M. Zbtb46 expression distinguishes classical dendritic cells 
and their committed progenitors from other immune lineages. J. Exp. Med. 209: 1135-
1152, 2012. 
Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Br. Med. Bull. 53: 
491-508, 1997. 
Sawai C.M., Sisirak V., Ghosh H.S., Hou E.Z., Ceribelli M., Staudt L.M., Reizis B. 
Transcription factor Runx2 controls the development and migration of plasmacytoid 
dendritic cells. J. Exp. Med. 201: 2151-2159, 2013. 
  126
Schäkel K., Kannagi R., Kniep B., Goto Y., Mitsuoka C., Zwirner J., Soruri A., von 
Kietzell M., Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, 
defines an inflammatory type of human dendritic cells. Immunity 17: 289-301, 2002. 
Schmidt S.V., Nino-Castro A.C., Schultze J.L. Regulatory dendritic cells: there is more 
than just immune activation. Front. Immunol. 3: 274, 2012. 
Schmuth M., Neyer S., Rainer C., Grassegger A., Fritsch P., Romani N., Heufler C. 
Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with 
impaired permeability barrier function. Exp. Dermatol. 11: 135-142, 2002. 
Schuler G., Ed. (1991) Epidermal Langerhans Cells. CRC Press Inc., Boca Raton. 
Schuler G., Steinman R.M. Murine epidermal Langerhans cells mature into potent 
immunostimulatory dendritic cells in vitro. J. Exp. Med. 161: 526-546, 1985. 
Schumacher A., Zenclussen A.C. Regulatory T cells: regulators of life. Am. J. Reprod. 
Immunol. 72: 158-170, 2014. 
Segura E., Amigorena S. Identification of human inflammatory dendritic cells. 
Oncoimmunology 2: e23851, 2013. 
Segura E., Touzot M., Bohineust A., Cappuccio A., Chiocchia G., Hosmalin A., Dalod 
M., Soumelis V., Amigorena S. Human inflammatory dendritic cells induce Th17 cell 
differentiation. Immunity 38: 336-348, 2013. 
Shen Z.H., Reznikoff G., Dranoff G., Rock K.L. Cloned dendritic cells can present 
exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158: 
2723-2730, 1997. 
Shigematsu H., Reizis B., Iwasaki H., Mizuno S., Hu D., Traver D., Leder P., 
Sakaguchi N., Akashi K. Plasmacytoid dendritic cells activate lymphoid-specific 
genetic programs irrespective of their cellular origin. Immunity 21: 43-53, 2004. 
Shin H., Iwasaki A. Tissue-resident memory T cells. Immunol. Rev. 255: 165-181, 
2013. 
Shortman K., Caux C. Dendritic cell development: multiple pathways to nature's 
adjuvants. Stem Cells. 15: 409-419, 1997. 
Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., 
Antonenko S., Liu Y.J. The nature of the principal type 1 interferon-producing cells in 
human blood Science, 284: 1835-1837,1999. 
Silberberg-Sinakin I. Apposition of mononuclear cells to Langerhans cells in contact 
allergic reactions. Acta dermato-venereol. 53: 1-12, 1973. 
Silberberg-Sinakin I., Thorbecke G.J., Baer R.L., Rosenthal S.A., Berezowsky V. 
Antigen-bearing Langerhans cells in skin dermal lymphatics and in lymph nodes. Cell. 
Immunol. 25: 137-151, 1976. 
Spiegelman B.M. Peroxisome proliferator-activated receptor gamma: a key regulator of 
adipogenesis and systemic insulin sensitivity. Eur J Med Res 2: 457-464, 1997. 
Spiegelman B.M. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. 
Diabetes 47:507-514, 1998. 
Spits H. (2001) Dendritc cells in the thymus. In: Lotze M.T., Thomson A.W. (Eds.) 
Dendritic Cells. 2nd edn. Academic Press, San Diego. Pp. 13-20. 
Sporn M.B., Roberts A.B. Transforming growth factor-beta: recent progress and new 
challenges. Cell Biol. 119: 1017-1021, 1992. 
Sprent J., Webb S.R. Intrathymic and extrathymic clonal deletion of T cells. Curr. Opin. 
Immunol. 7: 196-205, 1995. 
Springer T.A. Adhesion receptors of the immune system. Nature 346: 425-434, 1990. 
Stein-Streilein J. Immune regulation and the eye. Trends Immunol. 29: 548-554, 2008. 
Steinman R.M, Pack M., Inaba K. Dendritic cells in the T-cell areas of lymphoid 
organs. Immunological Reviews Vol. 156: 25-37, 1997. 
  127
 Steinman R.M. Decisions about dendritic cells: past, present, and future. Annu. Rev. 
Immunol. 30: 1-22, 2012. 
Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. 
Immunol. 9: 271-296, 1991. 
Steinman R.M., Cohn Z.A. Identification of a novel cell type in peripheral lymphoid 
organs of mice. I. Morphology, quantification, tissue distribution. J. Exp. Med. 137: 
1142-1162, 1973. 
Steinman R.M., Cohn Z.A. Identification of a novel cell type in peripheral lymphoid 
organs of mice. II. Functional properties in vitro. J. Exp. Med. 139: 380-397, 1974. 
Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. 
Rev. Immunol. 21: 685-711, 2003. 
Steinman R.M., Kaplan G., Witmer M.D., Cohn Z.A. Identification of a novel cell type 
in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new 
surface markers, and maintenance in vitro. J. Exp. Med. 149: 1-16, 1979. 
Steinman R.M., Mellman I. Immunotherapy: bewitched, bothered, and bewildered no 
more. Science (New York, N.Y.) 305: 197–200, 2004. 
Steinman R.M., Witmer M. Lymphoid dendritic cells are potent stimulators of the 
primary mixed leucocyte reaction in mice. Proc. Natl. Acad. Sci. USA 75: 5132-5136, 
1978. 
Stene MA, Babajanians M, Bhuta S, Cochran AJ. Quantitative alterations in cutaneous 
Langerhans cells during the evolution of malignant melanoma of the skin. J Invest 
Dermatol. 91: 125-128, 1988. 
Stingl G., Katz S. I., Clements L., Green I., Shevach E.M. Immunologic functions of Ia-
bearing epidermal Langerhans cells. J. Immunol. 121: 2005-2013, 1978. 
Stingl G., Wolff-Schreiner E.C., Pichler W.J., Gschnait F., Knapp W. Epidermal 
Langerhans cells bear Fc and C3 receptors. Nature 268: 245-246, 1977. 
Stöber W., Fink A., Bohn E. Controlled growth of monodisperse silica spheres in the 
micron size range. J. Colloid Interface Sci. 26: 62-69, 1968. 
Stoitzner P., Sparber F., Tripp CH. Langerhans cells as targets for immunotherapy 
against skin cancer. Immunol. Cell Biol. 88(4): 431-437, 2010. 
Süss G., Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-
induced apoptosis. J. Exp. Med. 183: 1789-1796, 1996. 
Swiecki M., Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat. 
Rev. Immunol. 15: 471-485, 2015. 
Szanto A., Benko S., Szatmari I., Balint B.L., Furtos I., Rühl R., Molnar S., Csiba L., 
Garuti R., Calandra S., Larsson H., Diczfalusy U., Nagy L.. Transcriptional regulation 
of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and 
liver X receptor signaling in macrophages. Mol. Cell Biol. 24: 8154-866, 2004. 
Szatmari I., Gogolak P., Im J.S., Dezso B., Rajnavolgyi E., Nagy L. Activation of 
PPARgamma specifies a dendritic cell subtype capable of enhanced induction of 
iNKT cell expansion. Immunity 21: 95-106, 2004. 
Szatmari I., Rajnavolgyi E., Nagy L. PPARgamma, a lipid-activated transcription factor 
as a regulator of dendritic cell function. Ann. N.Y. Acad. Sci. 1088: 207-218, 2006. 
Szatmari I., Töröcsik D., Agostini M., Nagy T., Gurnell M., Barta E., Chatterjee K., 
Nagy L. PPARgamma regulates the function of human dendritic cells primarily by 
altering lipid metabolism. Blood 110: 3271-3280, 2007. 
Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic- cell immunotherapy: 
from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7: 790-802, 2007. 
Tafuri A., Alferink J., Möller P., Hämmerling G.J., Arnold B.  T cell awareness of 
paternal alloantigens during pregnancy. Science 270: 630-633, 1995. 
  128
Takeda K., Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17: 1-14, 
2005. 
Tang A., Amagai M., Granger L.G., Stanley J.R., Udey M.C. Adhesion of epidermal 
Langerhans cells to keratinocytes mediated by E-cadherin. Nature 361: 82-85, 1993. 
Tel J., Sittig S.P., Blom R.A., Cruz L.J., Schreibelt G., Figdor C.G., de Vries I.J. Targeting 
uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-
presentation and robust type I IFN secretion. J. Immunol. 191: 5005-5012, 2013. 
Thappa D.M., Chiramel M.J.Evolving role of immunotherapy in the treatment of 
refractory warts. Indian. Dermatol. Online J. 7: 364-370, 2016. 
Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by 
PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994. 
Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARgamma 
promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 
241-252, 1998. 
Torchinsky M.B., Garaude J., Martin A.P., Blander J.M. Innate immune recognition of 
infected apoptotic cells directs TH17 cell differentiation. Nature 458: 78-82, 2009. 
Toriyama K., Wen D.R., Paul E., Cochran A.J. Variations in the distribution, frequency, 
and phenotype of Langerhans cells during the evolution of malignant melanoma of the 
skin. J. Invest. 100 (1 suppl.): 269S-273S, 1993. 
Töröcsik D., Bárdos H., Hatalyák Z., Dezső B., Losonczy G., Paragh L., Péter Z., Balázs 
M., Remenyik E., Adány R. Detection of factor XIII-A is a valuable tool for 
distinguishing dendritic cells and tissue macrophages in granuloma annulare and 
necrobiosis lipoidica. J. Eur. Acad. Dermatol. Venereol. 16: 1087-1096, 2014. 
Treilleux I., Blay J.Y., Bendriss-Vermare N., Ray-Coquard I., Bachelot T., Guastalla 
J.P., Bremond A., Goddard S., Pin J.J., Barthelemy-Dubois C., Lebecque S. Dendritic 
cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10: 7466-
74, 2004. 
Trucci M., Salum F.G., Figueiredo M.A., Cherubini K. Interrelationship of dendritic 
cells, type 1 interferon system, regulatory T cells and toll-like receptors and their role 
in lichen planus and lupus erythematosus - a literature review. Arch. Oral. Biol. 58: 
1532-1540, 2013. 
Turkevich J., Stevenson P.C., Hillier J. A study of the nucleation and growth processes 
in the synthesis of colloidal gold. Discuss Faraday Soc. 11: 55-75, 1951. 
Upadhyay J., Rao N.N., Upadhyay R.B. A comparative analysis of langerhans cell in 
oral epithelial dysplasia and oral squamous cell carcinoma using antibody CD-1a. J. 
Cancer Res Ther. 8: 591-597, 2012. 
Uzan-Gafsou S., Bausinger H., Proamer F., Monier S., Lipsker D., Cazenave J.P., Goud 
B., de la Salle H., Hanau D. and Salamero J. Rab11A controls the biogenesis of 
Birbeck granules by regulating Langerin recycling and stability. Mol. Biol. Cell. 18: 
3169-3179, 2007. 
Valentini P., Fiammengo R., Sabella S., Gariboldi M., Maiorano G., Cingolani R., 
Pompa P.P. Gold-nanoparticle-based colorimetric discrimination of cancer-related 
point mutations with picomolar sensitivity. ACS Nano. 7: 5530-5538, 2013. 
Valladeau J., Ravel O., Dezutter-Dambuyant C., Moore K., Kleijmeer M., Liu Y., 
Duvert-Frances V., Vincent C., Schmitt D., Davoust J., Caux C., Lebecque S., Saeland 
S. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic 
receptor that induces the formation of Birbeck granules. Immunity 12: 71-81, 2000. 
Valladeau J., Saeland S. Cutaneous dendritic cells. Semin Immunol. 17: 273-283, 2005. 
van de Winkel J.G., Capel P.J. Human IgG Fc receptor heterogeneity: molecular aspects 
and clinical implications. Immunol Today 14: 215-221, 1993. 
  129
Van den Bossche J., Malissen B., Mantovani A., De Baetselier P., Van Ginderachter 
J.A. Regulation and function of the E-cadherin/catenin complex in cells of the 
monocyte-macrophage lineage and DCs. Blood 119: 1623-1633, 2012. 
van Dinther D., Stolk D.A., van de Ven R., van Kooyk Y., de Gruijl T.D., den Haan 
J.M.M. Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells 
to improve cancer vaccines. J. Leukoc. Biol. 102: 1017-1034, 2017. 
van Panhuys N. Studying Dendritic Cell-T Cell Interactions Under In Vivo Conditions. 
Methods Mol. Biol. 1584: 569-583, 2017. 
Van Voorhis W., Hair L.S., Steinman R.M., Kappan G. Human dendritic cell 
enrichment and characterization from peripheral blood. J. Exp. Med. 155: 1172-1187, 
1982. 
Vandenabeele S., Hochrein H., Mavaddat N., Winkel K., Shortman K. Human thymus 
contains 2 distinct dendritic cell populations. Blood 97: 1733-1741, 2001. 
Varga T., Czimmerer Z., Nagy L. PPARs are a unique set of fatty acid regulated 
transcription factors controlling both lipid metabolism and inflammation. Biochim. 
Biophys. Acta 1812: 1007-1022, 2011. 
Varga T., Nagy L. Nuclear receptors, transcription factors linking lipid metabolism and 
immunity: the case of peroxisome proliferator-activated receptor gamma. Eur. J. Clin. 
Invest. 38: 695-707, 2008. 
Veerman A.J. On the interdigitating cells in the thymus-dependent area of the rat 
spleen: a relation between the mononuclear phagocyte system and T-lymphocytes. 
Cell Tissue Res. 148: 247-257, 1974. 
Veldman J.E. Histophysiology and electron microscopy of the immune response. 
Doctoral Thesis, University of Groningen, 1970. 
Veldman J.E., Kaiserling E. Interdigitating cells. In: Carr I., Daems W.T. (Eds.) The 
Reticuloendothelial System. A Comprehensive Treatise. 1. (1980) Morphology. 
Plenum, New York. Pp. 381-416. 
Villadangos J.A., Heath W.R. Life cycle, migration and antigen presenting functions of 
spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. 
Semin. Immunol. 17: 262-272, 2005. 
Von Bubnoff D., Geiger E., Bieber T. Antigen-presenting cells in allergy. J. Allergy 
Clin. Immunol. 108: 329-339, 2001. 
Vremec D., Shortman K. Dendritic cell subtypes in mouse lymphoid organs. The 
journal of Immunology 159: 565-573, 1997. 
Walkey C.D., Chan W.C.W. Understanding and controlling the interaction of 
nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41: 
2780-2799, 2012. 
Wang H.F., Liu J.L., Jiang X.L., Lu J.M., Li X.L., Song X.J. Suppressive effect of 
aqueous humor on lipopolysaccharide-induced dendritic cell maturation. Jpn.. J. 
Ophthalmol. 55: 558-564, 2011. 
Wang Q., Zhang M., Ding G., Liu Y., Sun Y., Wang J., Zhang W., Fu Z., Cao X. Anti-
ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to 
induce donor-specific immune tolerance in vivo. Immunol. Lett. 90: 33-42, 2003. 
Wang Y.P., Chen I.C., Wu Y.H., Wu Y.C., Chen H.M., Yu-Fong Chang J. Langerhans 
cell counts in oral epithelial dysplasia and their correlation to clinicopathological 
parameters. J. Formos. Med. Assoc. 116: 457-463, 2017. 
Wei-guo Z., Hui Y., Shan L., Yun Z., Wen-cheng N., Fu-lin Y., Fang-yan F., Jun-hua 
G., Jian-hua Z. PPAR-gamma agonist inhibits Ang II-induced activation of dendritic 
cells via the MAPK and NF-kappaB pathways. Immunol. Cell Biol. 88: 305-312, 
2010. 
  130
Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., Glass C.K. PPARgamma and 
PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma 
target genes in macrophages. Proc. Natl. Acad. Sci. U.S.A. 100: 6712-6717, 2003. 
Whiteside T.L., Stanson J., Shurin M.R., Ferrone S. Antigen-processing machinery in 
human dendritic cells: up-regulation by maturation and down-regulation by tumor 
cells. J. Immunol. 173: 1526-1534, 2004. 
Witmer M.D., Steinman R.M. The anatomy of peripheral lymphoid organs with 
emphasis on accessory cells: light-microscopic immunocytochemical studies of mouse 
spleen, lymph node, and Peyer's patch. Am. J. Anat. 170: 465-481, 1984. 
Witmer-Pack M.D., Olivier W., Valinsky J., Schuler G., Steinman R.M. 
Granulocyte/macrophage colony-stimulating factor is essential for the viability and 
function of cultured murine epidermal Langerhans cells. J. Exp. Med. 166: 1484-1498, 
1987. 
Wolff K. The fine structure of the Langerhans cell granule. J. Cell. Biol. 35: 468-73, 
1967. 
Woodham A.W., Skeate J.G., Sanna A.M., Taylor J.R., Da Silva D.M., Cannon P.M., 
Kast W.M. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, 
and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 
30: 291-306, 2016. 
Yin G.W., Li J. Confluent Atypical Molluscum Contagiosum Causing Disfigurement in 
a Human Immunodeficiency Virus Patient. Ann. Acad. Med. Singapore. 46: 37-38, 
2017. 
Young J.W., Steinman R.M. Dendritic cells stimulate primary human cytolytic 
lymphocyte responses in the absence of CD4+ helper T-cells. J. Exp. Med. 171: 1315-
1332, 1990. 
Zeis M., Siegel S., Wagner A., Schmitz M., Marget M., Kühl-Burmeister R., Adamzik 
I., Kabelitz D., Dreger P., Schmitz N., Heiser A. Generation of cytotoxic responses in 
mice and human individuals against hematological malignancies using survivin-RNA-
transfected dendritic cells. J. Immunol. 170 :5391-5397, 2003. 
Zhang Z., Wang F.S. Plasmacitoid dendritic cells act the most competent cell type in 
linking antiviral innate and adaptive immune responses. Cell. Mol. Immunol. 2: 411-
417, 2005. 
Zumwalde N.A., Domae E., Mescher M.F., Shimizu Y. ICAM-1-dependent homotypic 
aggregates regulate CD8 T cell effector function and differentiation during T cell 
activation. J. Immunol. 191: 3681-3693, 2013. 
 
